CLINICAL APPROPRIATENESS GUIDELINES

RADIATION ONCOLOGY

Appropriate Use Criteria: Brachytherapy, Intensity Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, and Stereotactic Radiosurgery

EFFECTIVE FEBRUARY 9, 2020

Proprietary

Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details. AIM Specialty Health disclaims any responsibility for the completeness or accuracy of the information contained herein.
# Table of Contents

CLINICAL APPROPRIATENESS GUIDELINES RADIATION ONCOLOGY ................................................................. 1

  Description and Application of the Guidelines ................................................................................................. 4
  General Clinical Guideline .............................................................................................................................. 5

Image Guidance in Radiation Oncology ............................................................................................................. 7

  General Information ........................................................................................................................................ 7
  Radiation Oncology Indications ....................................................................................................................... 10
  Coding ......................................................................................................................................................... 10
  References .................................................................................................................................................. 11

Special Treatment Procedure and Special Physics Consult .............................................................................. 13

  General Information ....................................................................................................................................... 13
  Radiation Oncology Indications ....................................................................................................................... 13
  Coding ......................................................................................................................................................... 14
  References .................................................................................................................................................. 14

Bone Metastases .................................................................................................................................................. 15

  General Information ....................................................................................................................................... 15
  Radiation Oncology Indications ....................................................................................................................... 17
  Coding ......................................................................................................................................................... 18
  References .................................................................................................................................................. 20

Breast Cancer ..................................................................................................................................................... 22

  General Information ....................................................................................................................................... 22
  Radiation Oncology Indications ....................................................................................................................... 25
  Coding ......................................................................................................................................................... 26
  References .................................................................................................................................................. 28

Central Nervous System Cancers: Intracranial, Spinal, Ocular, and Neurologic Indications ................................ 31

  General Information ....................................................................................................................................... 31
  Radiation Oncology Indications ....................................................................................................................... 32
  Coding ......................................................................................................................................................... 36
  References .................................................................................................................................................. 39

Colorectal and Anal Cancers .............................................................................................................................. 42

  General Information ....................................................................................................................................... 42
  Radiation Oncology Indications ....................................................................................................................... 43
  Coding ......................................................................................................................................................... 43
  References .................................................................................................................................................. 44

Gastrointestinal Cancers, Non-Colorectal: Cholangiocarcinoma, Esophageal, Gastric, Liver, Pancreatic ........... 46

  General Information ....................................................................................................................................... 46
  Radiation Oncology Indications ....................................................................................................................... 47
  Coding ......................................................................................................................................................... 50
  References .................................................................................................................................................. 52

Genitourinary Cancers: Bladder, Penile, and Testicular ...................................................................................... 54

  General Information ....................................................................................................................................... 54
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Oncology Indications</td>
<td>54</td>
</tr>
<tr>
<td>Coding</td>
<td>55</td>
</tr>
<tr>
<td>References</td>
<td>57</td>
</tr>
<tr>
<td>Gynecologic Cancers: Cervical, Fallopian Tube, Ovarian, Uterine, and Vulvar/Vaginal</td>
<td>58</td>
</tr>
<tr>
<td>General Information</td>
<td>58</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>59</td>
</tr>
<tr>
<td>Coding</td>
<td>60</td>
</tr>
<tr>
<td>References</td>
<td>62</td>
</tr>
<tr>
<td>Head and Neck Cancers (including Thyroid)</td>
<td>64</td>
</tr>
<tr>
<td>General Information</td>
<td>64</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>64</td>
</tr>
<tr>
<td>Coding</td>
<td>65</td>
</tr>
<tr>
<td>References</td>
<td>67</td>
</tr>
<tr>
<td>Lung Cancer: Small Cell and Non-Small Cell</td>
<td>68</td>
</tr>
<tr>
<td>General Information</td>
<td>68</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>69</td>
</tr>
<tr>
<td>Coding</td>
<td>71</td>
</tr>
<tr>
<td>References</td>
<td>73</td>
</tr>
<tr>
<td>Lymphoma: Hodgkin and Non-Hodgkin</td>
<td>75</td>
</tr>
<tr>
<td>General Information</td>
<td>75</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>76</td>
</tr>
<tr>
<td>Coding</td>
<td>76</td>
</tr>
<tr>
<td>References</td>
<td>78</td>
</tr>
<tr>
<td>Oligometastatic Extracranial Disease</td>
<td>80</td>
</tr>
<tr>
<td>General Information</td>
<td>80</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>81</td>
</tr>
<tr>
<td>Coding</td>
<td>81</td>
</tr>
<tr>
<td>References</td>
<td>82</td>
</tr>
<tr>
<td>Other Tumor Types: Sarcoma, Thymoma and Thymic Carcinoma, Pediatric Tumors, and Other Malignancies</td>
<td>84</td>
</tr>
<tr>
<td>General Information</td>
<td>84</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>85</td>
</tr>
<tr>
<td>Coding</td>
<td>86</td>
</tr>
<tr>
<td>References</td>
<td>88</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>90</td>
</tr>
<tr>
<td>General Information</td>
<td>90</td>
</tr>
<tr>
<td>Radiation Oncology Indications</td>
<td>92</td>
</tr>
<tr>
<td>Coding</td>
<td>94</td>
</tr>
<tr>
<td>References</td>
<td>96</td>
</tr>
<tr>
<td>Appendix 1 – CPT Groupers</td>
<td>99</td>
</tr>
<tr>
<td>History</td>
<td>101</td>
</tr>
</tbody>
</table>
Description and Application of the Guidelines

The AIM Clinical Appropriateness Guidelines (hereinafter “the AIM Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual. As used by AIM, the Guidelines establish objective and evidence-based criteria for medical necessity determinations where possible. In the process, multiple functions are accomplished:

- To establish criteria for when services are medically necessary
- To assist the practitioner as an educational tool
- To encourage standardization of medical practice patterns
- To curtail the performance of inappropriate and/or duplicate services
- To advocate for patient safety concerns
- To enhance the quality of health care
- To promote the most efficient and cost-effective use of services

The AIM guideline development process complies with applicable accreditation standards, including the requirement that the Guidelines be developed with involvement from appropriate providers with current clinical expertise relevant to the Guidelines under review and be based on the most up-to-date clinical principles and best practices. Relevant citations are included in the References section attached to each Guideline. AIM reviews all of its Guidelines at least annually.

AIM makes its Guidelines publicly available on its website twenty-four hours a day, seven days a week. Copies of the AIM Clinical Appropriateness Guidelines are also available upon oral or written request. Although the Guidelines are publicly-available, AIM considers the Guidelines to be important, proprietary information of AIM, which cannot be sold, assigned, leased, licensed, reproduced or distributed without the written consent of AIM.

AIM applies objective and evidence-based criteria, and takes individual circumstances and the local delivery system into account when determining the medical appropriateness of health care services. The AIM Guidelines are just guidelines for the provision of specialty health services. These criteria are designed to guide both providers and reviewers to the most appropriate services based on a patient’s unique circumstances. In all cases, clinical judgment consistent with the standards of good medical practice should be used when applying the Guidelines. Guideline determinations are made based on the information provided at the time of the request. It is expected that medical necessity decisions may change as new information is provided or based on unique aspects of the patient’s condition. The treating clinician has final authority and responsibility for treatment decisions regarding the care of the patient and for justifying and demonstrating the existence of medical necessity for the requested service. The Guidelines are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.

The Guidelines do not address coverage, benefit or other plan specific issues. Applicable federal and state coverage mandates take precedence over these clinical guidelines. If requested by a health plan, AIM will review requests based on health plan medical policy/guidelines in lieu of the AIM Guidelines.

The Guidelines may also be used by the health plan or by AIM for purposes of provider education, or to review the medical necessity of services by any provider who has been notified of the need for medical necessity review, due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner.
General Clinical Guideline

Clinical Appropriateness Framework

Critical to any finding of clinical appropriateness under the guidelines for a specific diagnostic or therapeutic intervention are the following elements:

- Prior to any intervention, it is essential that the clinician confirm the diagnosis or establish its pretest likelihood based on a complete evaluation of the patient. This includes a history and physical examination and, where applicable, a review of relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention.
- The anticipated benefit of the recommended intervention should outweigh any potential harms that may result (net benefit).
- Current literature and/or standards of medical practice should support that the recommended intervention offers the greatest net benefit among competing alternatives.
- Based on the clinical evaluation, current literature, and standards of medical practice, there exists a reasonable likelihood that the intervention will change management and/or lead to an improved outcome for the patient.

If these elements are not established with respect to a given request, the determination of appropriateness will most likely require a peer-to-peer conversation to understand the individual and unique facts that would supersede the requirements set forth above. During the peer-to-peer conversation, factors such as patient acuity and setting of service may also be taken into account.

Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions

Requests for multiple diagnostic or therapeutic interventions at the same time will often require a peer-to-peer conversation to understand the individual circumstances that support the medical necessity of performing all interventions simultaneously. This is based on the fact that appropriateness of additional intervention is often dependent on the outcome of the initial intervention.

Additionally, either of the following may apply:

- Current literature and/or standards of medical practice support that one of the requested diagnostic or therapeutic interventions is more appropriate in the clinical situation presented; or
- One of the diagnostic or therapeutic interventions requested is more likely to improve patient outcomes based on current literature and/or standards of medical practice.

Repeat Diagnostic Intervention

In general, repeated testing of the same anatomic location for the same indication should be limited to evaluation following an intervention, or when there is a change in clinical status such that additional testing is required to determine next steps in management. At times, it may be necessary to repeat a test using different techniques or protocols to clarify a finding or result of the original study.

Repeated testing for the same indication using the same or similar technology may be subject to additional review or require peer-to-peer conversation in the following scenarios:

- Repeated diagnostic testing at the same facility due to technical issues
- Repeated diagnostic testing requested at a different facility due to provider preference or quality concerns
- Repeated diagnostic testing of the same anatomic area based on persistent symptoms with no clinical change, treatment, or intervention since the previous study
- Repeated diagnostic testing of the same anatomic area by different providers for the same member over a short period of time
Repeat Therapeutic Intervention

In general, repeated therapeutic intervention in the same anatomic area is considered appropriate when the prior intervention proved effective or beneficial and the expected duration of relief has lapsed. A repeat intervention requested prior to the expected duration of relief is not appropriate unless it can be confirmed that the prior intervention was never administered.
Image Guidance in Radiation Oncology

General Information

Modalities used in Image Guidance

- Ultrasound-based guidance
- Stereoscopic x-ray guidance
- CT based image guidance
- Real-time intrafraction guidance

Radiation Oncology Considerations

Image guidance, also known as image-guided radiation therapy (IGRT), refers to pretreatment imaging used to verify correct patient positioning in cases where sub-centimeter accuracy is needed. There are multiple different technologies which can be utilized for IGRT including ultrasound visualization, stereoscopic x-ray guidance, computed tomography based guidance and continuous intra-fraction position monitoring. Both the American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) have published descriptive overviews and guidance related to the available methods, performance, quality assurance, limitations and safety aspects of image-guided therapy.

IGRT is an integral part of the delivery of highly conformal treatments such as intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). Recognition of this fact has resulted in changes to the current procedural terminology (CPT) definitions such that the technical aspect of IGRT is now bundled with IMRT delivery. Similarly, image guidance procedures have always been bundled for SBRT and SRS.

When highly tailored dose distributions such as IMRT and stereotactic radiation therapy are not being utilized, sub-centimeter precision is not generally needed and accurate patient setup is achieved with other techniques. These include patient immobilization with custom treatment devices like body molds or thermoplastic masks, placement of tattoos aligned to a 3-dimentional laser array in the treatment room and offline review of port verification films. Small daily setup uncertainties exist and these are taken into account in the target expansion process where an additional margin is added to the gross tumor volume (GTV) to create the clinical target volume (CTV) and ultimately the planning target volume (PTV) during the treatment planning process.

Pretreatment image acquisition and isocenter shifting has been suggested as a strategy to allow a safe reduction in PTV margins. By decreasing the volume of normal tissue exposed to radiation, the use of IGRT with 3D conformal radiation or IMRT has been suggested as a way to reduce toxicity, allow an increase in the radiation dose, or both. This has been most extensively studied in prostate cancer, where evidence of a dose response and improved freedom from failure with dose escalation from 70 Gy to 78 Gy was demonstrated in a randomized trial of intermediate to high risk patients treated with radiotherapy. The higher dose treatment was associated with increased rectal toxicity and this was correlated with the proportion of the rectal volume receiving > 70 Gy. This prompted efforts to dose escalate beyond 78 Gy and simultaneously decrease normal tissue toxicity by using IGRT, IMRT, and ultimately image-guided IMRT.

When used with 3D conformal radiation, IGRT has been shown to reduce late toxicities after prostate cancer radiotherapy. A study by Gill showed that patients treated with IGRT had significantly lower rates of > grade 3 urinary frequency (7% vs 23%), > grade 2 diarrhea (3% vs 15%) and fatigue (8% vs 23%) compared to patients treated without IGRT despite higher dose treatment in the IGRT patients. Another report by Singh demonstrated that treatment with IGRT significantly decreased reports of post-treatment rectal pain (odds ratio [OR] 0.07), urgency (OR 0.27), diarrhea (OR 0.009) and change in bowel habits (OR 0.18) compared to patients treated without IGRT. There was no difference in genitourinary symptoms reported in that study.

Multiple reports have also shown reduced late toxicities after high dose IMRT for prostate cancer compared to 3D conformal radiotherapy. Zelefsky reported 10 year follow-up comparing toxicity for prostate patients treated...
with IMRT versus 3D conformal radiotherapy and found that > grade 2 gastrointestinal complaints were significantly lower in the IMRT group (5% vs 13%). One criticism of these studies is that they were performed in the pre-IGRT era and it is unclear whether IGRT and IMRT both independently reduce toxicity. Comparing 3D and IMRT for patients who were all treated with implanted fiducial based image-guidance, IMRT resulted in significantly lower rectal doses and subsequent late rectal toxicity. Finally, the use of image-guided IMRT (IG-IMRT) with implanted fiducial markers has been shown to improve 3-year biochemical control and decrease late urinary toxicity in high-risk prostate patients compared to patients treated to the same dose (86.4 Gy) with IMRT but without IGRT.

Studies of post-prostatectomy IMRT have demonstrated superior dose distribution to the target volume with the use of IMRT, as compared with 3D conformal radiation delivery, with better sparing of nearby critical healthy tissue structures and less severe toxicity-related morbidity. The use of pretreatment cone beam CT image-guidance to a median dose of 68.4 Gy has been compared to post-operative radiotherapy using weekly port films to a dose of 64.8 Gy. Despite treatment to a higher dose, the IGRT group was noted to have similar genitourinary and gastrointestinal toxicities. Pretreatment corrective left-right, anteroposterior and superoinferior shifts were required in 15%, 6% and 19% of cases respectively supporting the use of pretreatment imaging. The ACR-ASTRO practice parameter for IGRT indicates that “when the target is not clearly visible and bony anatomy is not sufficient for adequate target alignment, fiducial markers may be needed.” For soft tissue targets such as the prostate, implanted fiducial markers have been validated as an accurate way to localize the target when using orthogonal imaging. Based on this research in prostate cancer, use of implanted fiducial markers for other soft tissue targets located in close proximity to critical structures is appropriate when needed to safely reduce PTV margins and reduce the risk of late complications.

In the setting of head and neck cancer, IGRT has been shown to allow a safe reduction of margin expansion and the ability to detect significant anatomic changes which might benefit from re-planning. Chen has reported a series of 225 consecutively treated head and neck cancer patients treated with image-guided IMRT. IGRT was performed with either kilovoltage or megavoltage volumetric imaging prior to each treatment. The first 95 patients were treated with a 5 mm CTV to PTV expansion and the following 130 patients were treated with a 3 mm expansion. Two year local control was equal for the two groups. Examination of the treatment failures did not reveal any marginal recurrences in either cohort. The authors concluded that when IGRT is used, the CTV to PTV margin can safely be reduced to 3 mm. A subsequent report included an additional 134 patients with 3 mm margin expansions (264 total) and found that the 3-year locoregional control was equal in the two groups. Compared to the 5 mm margin group, the 3 mm margin patients had a lower incidence of gastrostomy-tube dependence at 1 year (10% vs 3%, p=0.001) and esophageal stricture (14% vs 7%, p=0.01). IGRT can also help identify patients who would benefit from adaptive replanning to prevent overdose of critical structures such as the spinal cord if significant weight loss occurs during treatment. Essentially all of the research around IGRT for head and neck cancer has been performed in the setting of IMRT. There are no data supporting the use of IGRT for head and neck cancer patients treated with 3D conformal radiotherapy.

IGRT in the non-IMRT setting can be justified in cases where the use of surface tattoos and standard immobilization techniques are known to be inadequate. In obese patients with deep seated tumors of the abdomen and pelvis, surface landmarks are known to be inaccurate. In a study performed before the term image-guidance was coined, the authors report the need to shift an average of 11.4 mm in left-right axis and 7.2 mm in the superior-inferior axis in order to properly align obese patients receiving pelvic radiotherapy for prostate cancer based on pretreatment portal imaging. Wong has also reported that using computed tomography based IGRT, shifts of greater than 10 mm were needed 21.2% of the time to correctly position the prostate in moderately to severely obese patients (BMI > 35). This was significantly more than shifts needed in normal weight, overweight and mildly obese patients. ASTRO has used this scenario as an example of where IGRT may be required in conjunction with three-dimensional conformal radiotherapy in their Health Policy Coding Guidance document.

A recent study of the setup accuracy for lung cancer treatment showed that when compared to tattoos, using cone beam CT registration to the spine and carina improved target coverage approximately 50% of the time. Even using skin tattoos, however, the combined lung and nodal targets were found to be within the PTV over 97% of the time.

Tumor motion during the breathing cycle needs to be evaluated and managed when highly conformal radiation techniques are used to treat lung cancer. Liu evaluated respiratory related tumor motion in 152 patients with
lungs and found that motion in the superoinferior (SI) axis was > 0.5 cm in 39% of patients and > 1 cm in 11% of patients. The degree of respiratory cycle related motion was more pronounced with smaller lesions and with tumors further from the lung apex. Four dimensional CT (4DCT) scan planning coupled with IMRT is associated with improved overall survival (HR 0.64) and a decreased risk of > grade 3 pneumonitis (HR 0.33) compared to 3D conformal radiotherapy. The volume of lung receiving 20 Gy (V20) was significantly lower in the 4DCT/IMRT group. The American Association of Physicists in Medicine (AAPM) Task Group 76 guidelines summarized the adequate methods to account for this respiratory motion including 4DCT, slow CT, inhale/exhale/breath-hold CT, respiratory gating with internal fiducial markers or external markers to signal respiration, breath hold, abdominal compression for shallow breathing and real time tracking. There are no studies supporting the use of IGRT for lung cancer in the 3D conformal setting.

With left sided breast cancers, there is concern about cardiac toxicity due to the proximity of the heart to the treatment field. Intensity modulated radiation therapy (IMRT) has been used to decrease the cardiac dose during left sided radiation treatment. Image-guided deep inspiration breath hold (DIBH) techniques have been demonstrated to reduce cardiac exposure to radiation. A feasibility of IGRT for cardiac sparing in patients with left-sided breast cancer was investigated in a prospective study authored by Borst. Nineteen patients with left-sided breast cancer were treated with the deep inspiration breath hold (DIBH) technique during IGRT. Use of DIBH in these patients reduced mean cardiac dose (1.7 Gy vs. 5.1 Gy), the maximum dose (37 Gy vs. 49 Gy) and the volume of heart receiving 30 Gy (0.3 cc vs. 6.3 cc) compared with the free breathing technique. Similar results have been described in a larger series of 50 patients recently published by Cosma. Patients were eligible for inclusion in this study if an absolute volume of 10cc received more than 50% of the prescription dose (D10cc > 50%) based on criteria described by Wang. In these patients, the D10cc was reduced from 34.8 Gy for the free breathing group to 6.7 Gy for the DIBH group (p < 0.001).

For the majority of cases treated with 3D conformal radiotherapy, there is no evidence that the routine use of IGRT results in clinical benefit. Regarding clinical outcomes associated with IGRT, a recent review article concluded that "results of current and future clinical trials will hopefully demonstrate the net gain in therapeutic ratio from application of IGRT technologies and the onus lies on the radiation oncology community to take up the challenge of demonstrating the benefit of expensive IGRT approaches."

Multiple publications have documented the additional radiation exposure which occurs in conjunction with IGRT. Patient doses range from 1-3 mGy for gantry mounted kV systems to between 10 and 50 mGy per image for cone beam and fan beam CT scans. As with any medical procedure, the risks of radiation exposure must be weighed against the benefits of daily imaging. In situations where there is a lack of demonstrable benefit, concern about potential harms of this technology are relevant. Even in clinical scenarios where IGRT is considered medically necessary, the technique chosen should expose the patient to the minimum amount of radiation needed to achieve adequate visualization.

The National Comprehensive Cancer Network (NCCN) recommends using IGRT when using stereotactic body radiation therapy (SBRT) and when 3D conformal radiation or IMRT is used with steep dose gradients around the target, organs at risk are in close proximity to target tissues and when utilizing gating or other motion management techniques.

For breast cancer, NCCN states that routine use of daily imaging is not recommended.

## Society Recommendations

ASTRO/ACR – The American Society of Radiation Oncology (ASTRO) and The American College of Radiology (ACR) have published practice guidelines for image-guided radiation therapy (IGRT). The technologies for performing IGRT are described. The document also reviews suggested qualifications and responsibilities of the personnel involved in the performance of IGRT. The authors note that IGRT can be used to enhance either 3D conformal radiotherapy or intensity modulated radiation therapy (IMRT) but do not elaborate on clinical necessity for IGRT with either of these modalities. IGRT is noted to be a necessary and integral part of stereotactic body radiation therapy (SBRT). Elements of interfraction and intrafraction target motion are discussed. Fiducial marker placement and migration are reviewed. As part of the process of IGRT implementation, it is suggested that the radiation oncologist develop clinical guidelines outlining when physician involvement in verification of patient positioning is needed. No clinical outcomes are discussed.
Radiation Oncology Indications

Image guidance, any modality, is appropriate when ANY of the following conditions are met:

- Intensity modulated radiation therapy (IMRT) is being utilized
- Proton beam therapy is being utilized
- Use of IGRT will allow significant reduction of radiation dose to sensitive normal structures, for example:
  - Left-sided breast cancer treatment with deep inspiration breath hold technique (DIBH) for cardiac sparing is being utilized
- Implanted fiducial markers have been placed
- Bony anatomy fails to accurately delineate a tumor location and fiducial markers or intensity modulated radiation therapy (IMRT) are not indicated (for example, head and neck cancer or prone breast radiotherapy)
- The treatment field abuts a previously irradiated field
- There is significant setup variation affecting the treatment target, for example:
  - Individual is morbidly obese (BMI>35) and receiving treatment of tumors in the mediastinum, abdomen or pelvis
  - There is significant organ movement due to respiration and a 4D planning CT scan was performed with documentation demonstrating that the treatment plan addresses tumor motion that is both accounted for and managed

Note: Image guidance not meeting any of the above criteria is considered not medically necessary.

Frequency

When authorized, image guidance should be performed at the minimum frequency needed to assure proper patient positioning.

Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

CPT/HCPCS

Note: The work associated with CT scan acquisition for 3D or IMRT planning is bundled with codes 77295 and 77301, respectively. CPT code 77014 should NOT be billed in this setting.

77014 .......... CT guidance for placement of radiation therapy fields
77387 .......... Guidance for localization of target volume for delivery of radiation treatment delivery, includes intrafraction tracking, when performed
G6001 .......... Ultrasonic guidance for placement of radiation therapy fields
G6002 .......... Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy
G6017 .......... Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment
ICD-10 Diagnoses

All inclusive

References


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Special Treatment Procedure and Special Physics Consult

General Information

Radiation Oncology Considerations

**Special treatment procedure**, CPT® code 77470, describes the extra time, effort and resources associated with complex radiation therapy procedures and situations which are not reimbursed by another CPT® code. Several of these procedures are specifically described in the CPT® code definition including total body irradiation, hemibody radiation and per oral or endocavitary radiation. This code may also be used to report additional work and effort when a patient receives brachytherapy or concurrent chemotherapy along with a course of external beam radiation therapy. This code should not be used to report the work effort which is specifically described another CPT® code including but not limited to intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) or intraoperative radiation therapy (IORT).

**Special physics consult**, CPT® code 77370, describes work performed by a qualified medical physicist to address a specific question or problem related to a complex radiation therapy plan. This only applies when the query to the physicist is beyond the scope of the routine physics work effort associated with radiation therapy planning and delivery. In response to a physician request, the physicist prepares a customized written report specifically addressing the issue in question. A special physics consult may be appropriate in cases of brachytherapy where the physicist is directly involved or when an a composite plan is generated by the physicist to reflect cumulative doses from different radiation modalities such as photons, electrons, charges particles and gamma rays. A special physics consult is also medically necessary when radiation dose to a fetus or medical device such as pacemaker needs to be measured. Special physics consult is appropriate when the physicist performs a fusion multiple images sets with or without associated dose distributions to be used by the physician in the development or analysis of a treatment plan. This code should not be used when fusion is performed by a non-physicist. A special physics consult may also apply to other specific treatment related questions when ordered by the radiation oncologist and appropriate documentation is provided.

Radiation Oncology Indications

**Special treatment procedure** is indicated when extra planning time and effort can be documented for ANY of the following:

- Concurrent intravenous (I.V.) chemotherapy
- Brachytherapy
- Proton therapy
- Total body or hemibody radiation
- Pediatric patient requiring anesthesia
- Hyperthermia
- Reconstruction of previous radiation plan
- Stereotactic body radiation therapy (SBRT)
- Other (documentation of special circumstances or time consuming plan required)

**Special physics consult** is indicated when requested by physician for ANY of the following:

- Brachytherapy
- Fusion of multiple image sets (CT, MRI, PET) when performed by the medical physicist
- Dosimetric analysis of previous radiation field overlapping or abutting current field
- Analysis of dose to a fetus
- Analysis of dose to a pacemaker
- Stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) with report of dosimetric parameters and specific organ tolerances met or exceeded
- Other specific physics work not described by another CPT code, at request of radiation oncologist

**Frequency**

Special treatment procedure and special physics consults may each only be billed once per course of therapy

**Coding**

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

**CPT**

77370 ................. Special medical radiation physics consultation
77470 .................. Special treatment procedure

**ICD-10 Diagnoses**

All inclusive

**References**

Bone Metastases

General Information

Commonly Used Modalities

External Beam Radiation Therapy
- 2D and 3D conformal (EBRT)
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Initial treatment

Metastasis to the bony skeleton is a common site of spread for many solid tumors including breast, prostate and lung cancers. Bone metastases can be seen with any cancer histology and affects more than 250,000 patients per year in the United States. It has been estimated that up to 80% of patients with solid cancers will develop painful bone metastases to the pelvis, spine or extremities during the course of their illness. Metastases to the bone can cause accelerated bone breakdown which may result in pain, pathologic fracture and nerve or spinal cord compression resulting in sensory loss or motor weakness. Laboratory abnormalities may include hypercalcemia and myelosuppression. Radiation therapy has long been used to palliate pain and other symptoms of bone metastases with excellent results.

There have been multiple prospective, randomized, controlled clinical trials comparing different radiation fractionation schemes for bony metastases. Most of these trials have excluded patients with spinal cord compression or pathologic fracture at presentation. All of these trials, as well as several subsequent meta-analyses of these data, have concluded that for uncomplicated patients a single fraction of 8 Gy provides equivalent palliation to more prolonged fractionation over 1-4 weeks. The overall response rate with either regimen was approximately 60% with about 24% of patients demonstrating a complete response to treatment. Acute toxicity was found to be equivalent or better in the single fraction arms. There was no significant difference in pathologic fracture risk or subsequent spinal cord compression. The main difference which has been demonstrated is a higher rate of re-treatment with single fraction treatment versus more prolonged fractionation (20% vs 8%).

Because of the higher rate of re-treatment with single fraction radiotherapy, the use of fractionated regimens has been suggested for patients with bony metastasis from prostate and breast cancers. Analysis of the Dutch Bone Metastasis Study found equal pain relief and duration in patients with favorable prognosis. This has also been studied prospectively by the RTOG which looked specifically at whether prolonged fractionation resulted in superior palliation in patients with breast and prostate cancers. It was concluded that both single fraction and multifraction regimens were equally effective even in this favorable group of patients. The breast cancer expert panel of the German Society for Radiation Oncology (DEGRO) recommends fractionated regimens for breast cancer patients with oligometastatic bony metastasis and when the therapeutic goal is stabilization of disease as opposed to pain control. The NCCN guidelines for prostate cancer recommend that 8 Gy as a single dose be used instead of 30 Gy in 10 fractions for non-vertebral metastases.

In 2011, ASTRO published a guideline providing recommendations for palliative radiotherapy as a treatment for bone metastases. ASTRO’s recommendations were based on the findings of their systematic review of the peer-reviewed literature on palliative RT for bone metastases combined with the expert opinion of the Task Force members. With regards to the most effective fractionation scheme for the treatment of painful and/or prevention of morbidity from peripheral bone metastases, the ASTRO task force indicated that: “Multiple prospective randomized trials have shown pain relief equivalency for dosing schema, including 30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, and a single 8-Gy fraction for patients with previously unirradiated painful bone metastases. Fractionated RT courses have been associated with an 8% repeat
treatment rate to the same anatomic site because of recurrent pain vs. 20% after a single fraction; however, the single fraction treatment approach optimizes patient and caregiver convenience.”

ASTRO recently published an update of their evidence-based guideline which reviewed 20 new randomized trials, 32 new prospective non-randomized trials and 4 meta-analyses. The literature continues to support the equivalent pain relief of a single 8 Gy treatment compared to multifraction therapy.

Special circumstances have been identified where more prolonged fractionation may be preferable. These include individuals with soft tissue involvement causing neuropathic symptoms, spinal metastases, impending or outright spinal cord compression, and presence of oligometastatic disease. Most of these trials exploring different radiation fractionation schemes for bony metastases have excluded subjects with spinal cord compression or pathologic fracture at presentation.

The study by Roos et al. looked at single fraction versus fractionated radiotherapy for patients with neuropathic pain and found that the time to treatment failure was shorter in the single fraction regimen. The risk of developing spinal cord compression in patients with vertebral bony metastasis has been found to be slightly higher with single fraction treatment, although this did not reach statistical significance and the overall risk of cord compression was less than 6% in both groups.

ASTRO indicated that while many of the peer-reviewed studies did not make a distinction between treatment relief for spinal vs non-spinal metastases, the task force was able to conclude that there was no evidence to suggest that a single 8-Gy fraction was less effective in providing pain relief than a more prolonged RT course in painful spinal sites. The authors also concluded that there were not “any suggestions from the available data that single-fraction therapy produces unacceptable rates of long-term side effects that might limit this fractionation schedule for patients with painful bone metastases.”

A recent report by Lam explores factors affecting adverse outcomes in 299 patients receiving palliative radiotherapy for uncomplicated spine metastases. The cumulative incidence of first skeletal adverse event (SAE) at 180 days was 23.6% for single fraction (SF) radiation versus 9.2% for multiple fraction (MF) treatment. On multivariate analysis, single fraction treatment (HR 2.8, p=0.001) and baseline spine instability score (HR 2.5, p=0.007) were significant predictors of the incidence of first SAE. To account for baseline differences, outcomes were compared using a propensity score matched analysis. They found that the 90 day incidence of SAEs was 22% for patients treated with SF radiotherapy versus 6% for patients treated with a MF regimen (HR 3.9, p=0.003). Spinal adverse events were defined as a symptomatic fracture, hospitalization for site-related pain, salvage surgery, interventional procedure, new neurologic symptoms or cord compression.

Radiation therapy is a common treatment for metastatic spinal cord compression. In patients with a single site of compression and life expectancy of at least 3 months, surgical decompression should be considered as it has been shown to preserve neurologic function better than radiotherapy alone in a phase III randomized study. Post-operative radiotherapy should be given in these patients. 30 Gy in 10 fractions has been the most commonly used. No reports have been published regarding the use of single fraction palliative EBRT in the post-operative setting. For patients who are not candidates for surgery, radiation therapy should be given after initiation of corticosteroid therapy. A recent review of radiation therapy for metastatic spinal cord compression concluded that for patients with a poor prognosis, a single fraction of 8 Gy should be given. For those with patients with a good prognosis, consideration of 30 Gy in 10 fractions was recommended.

When a metastasis results in a pathologic compression fracture, percutaneous kyphoplasty may be of benefit. The ASTRO evidence based guideline concluded that no prospective data are available to suggest that the use of either kyphoplasty or vertebroplasty obviates the need for EBRT in the management of painful bone metastases.

Stereotactic body radiation therapy (SBRT) or stereotactic ablative body radiotherapy (SABR) is being studied in the treatment of bony metastatic disease. Proposed indications for this modality include standalone or postoperative treatment in patients with progressive or recurrent disease following conventional external beam radiotherapy (cEBRT) and in the treatment of tumors traditionally considered radioresistant to cEBRT such as sarcoma, melanoma and renal cell carcinoma. The RTOG is currently conducting a comparison of SBRT with a single fraction of 8 Gy for painful vertebral metastasis. The updated ASTRO evidence-based guideline maintains that: “Advanced RT techniques such as SBRT as the primary treatment for painful spine bone lesions or for spinal cord compression should be considered in the setting of a clinical trial or with data collected in a registry given that insufficient data are available to routinely support this treatment currently.”
Repeat treatment

Following initial treatment with radiation therapy for bony metastasis, some patients will develop recurrent or progressive symptoms for which additional radiation therapy is indicated. Studies have shown repeat radiation therapy to be effective in reducing pain in approximately 48% of patients. Responders have been shown to have improved quality of life. When a given site is re-treated, the effect of prior irradiation on the surrounding normal tissues must be taken into account. This is especially important when treating vertebral lesions where the cumulative dose to the spinal cord must be minimized. The generally accepted maximum cumulative dose to the spinal cord is 50 Gy in 2 Gy fractions (or equivalent). If repeat radiation using 2D or 3D techniques would result in a cumulative dose to the spinal cord greater than 50 Gy in 2 Gy fractions then consideration should be given to intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), or stereotactic body radiation therapy (SBRT).

Society Recommendations

ASTRO – The 2013 Choosing Wisely campaign included as one of its 5 recommendations that fractionation beyond 10 treatments should not be routinely used to treat bone metastases. They noted that 8 Gy in a single fraction results in equivalent pain relief compared to 20 Gy in 5 fractions or 30 Gy in 10 fractions. They suggested that strong consideration be given to 8 Gy in a single fraction for patient with poor prognosis or transportation difficulties.

ACR – The American College of Radiology has published Appropriateness Criteria for both spinal and nonspinal bone metastases. They note that radiation therapy is the mainstay of treatment for bony metastatic lesions. They list several fractionation regimens including 30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, or a single 8 Gy fraction. They note that randomized clinical trials have shown equivalent pain relief for all of these regimens.

Radiation Oncology Indications

2D or 3D Conformal External Beam Radiation Therapy (EBRT) is appropriate for bone metastases when ANY one of the following conditions are met:

- Pain at the site of metastasis
- Lytic lesion involving a weight bearing bone
- Spinal cord compression
- Post-operative treatment following surgical stabilization

Intensity Modulated Radiation Therapy (IMRT) is appropriate for bone metastases when ALL of the following conditions are met:

- To treat a previously irradiated field
- Re-treatment with EBRT would result in significant risk of adjacent organ injury

Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT) is appropriate for bone metastasis when ALL of the following conditions are met:

- To treat a previously irradiated field
- Re-treatment with EBRT would result in significant risk of adjacent organ injury

Note: When SRS/SBRT is being requested to treat a patient with oligometastatic disease with potentially curative intent, please refer to separate criteria in the Oligometastatic Extracranial Disease section of the Guidelines.
Fractionation

Single fraction treatment is appropriate in individuals who meet the following criterion:

- Goal of therapy is pain relief

Fractionated radiotherapy, 2 to 10 fractions, is only appropriate in individuals who meet the following criteria:

- Fair to good performance status, defined as Karnofsky (KPS) > 60 or ECOG status 0-2 and any of the following:
  - Pathologic fracture
  - Soft tissue involvement by tumor
  - Spinal cord compression
  - Spine metastasis
  - Presence of oligometastatic disease (1-5 lesions) when the goal of treatment is long term stabilization of disease

Fractionation beyond 10 treatments is not medically necessary

Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

2D and 3D Conformal

CPT/HCPCS

77295 ......................... 3-dimensional radiotherapy plan, including dose-volume histograms (3D Conformal treatment plan)
77402 ......................... Radiation treatment delivery, > 1 MeV; simple.
77407 ......................... Radiation treatment delivery, > 1 MeV; intermediate.
77412 ......................... Radiation treatment delivery, > 1 MeV; complex.
G6003 ......................... Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 MeV
G6004 ......................... Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 MeV
G6005 ......................... Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 MeV
G6006 ......................... Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 MeV or greater
G6007 ......................... Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5 MeV
G6008 ......................... Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10 MeV
G6009 ......................... Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19 MeV
G6010 ......................... Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20 MeV or greater
G6011 ............... Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 MeV
G6012 ............... Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV
G6013 ............... Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV
G6014 ............... Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater

**Intensity Modulated Radiation Therapy (IMRT)**

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>77301 .................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (IMRT treatment plan)</td>
</tr>
<tr>
<td>77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan</td>
</tr>
<tr>
<td>77386 .................. Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking when performed; complex</td>
</tr>
<tr>
<td>G6015 .................. Intensity modulated Treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session</td>
</tr>
<tr>
<td>G6016 .................. Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session</td>
</tr>
</tbody>
</table>

**Stereotactic Body Radiation Therapy**

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>63620 .................. Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); one spinal lesion</td>
</tr>
<tr>
<td>63621 .................. Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each add’l spinal lesion</td>
</tr>
<tr>
<td>77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms (3D Conformal treatment plan)</td>
</tr>
<tr>
<td>77301 .................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (IMRT treatment plan)</td>
</tr>
<tr>
<td>77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan</td>
</tr>
<tr>
<td>77370 .................. Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77373 .................. Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77435 .................. Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77470 .................. Special treatment procedure</td>
</tr>
<tr>
<td>G0339 .................. Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment</td>
</tr>
<tr>
<td>G0340 .................. Image-guided robotic linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions; maximum five sessions per course of treatment</td>
</tr>
</tbody>
</table>

**Stereotactic Radiosurgery**

<table>
<thead>
<tr>
<th>CPT/ HCPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>63620 .................. Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); one spinal lesion</td>
</tr>
<tr>
<td>63621 .................. Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each add’l spinal lesion</td>
</tr>
<tr>
<td>77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77301 .................. Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)</td>
</tr>
<tr>
<td>77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan</td>
</tr>
<tr>
<td>77370 .................. Special medical radiation physics consultation</td>
</tr>
</tbody>
</table>
77371 ................. Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based

77372 ................. Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based

77432 ................. Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)

G0339 ................. Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment

G0340 ................. Image-guided robotic linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions; maximum five sessions per course of treatment

All modalities

ICD-10 Diagnoses

C79.51 - C79.52... Secondary malignant neoplasm of bone and bone marrow

References


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Breast Cancer

General Information

Commonly Used Modalities

- Internal Radiation Therapy (Brachytherapy)
- External Beam Radiation Therapy
  - 2D and 3D conformal
  - Intensity Modulated Radiation Therapy (IMRT)

Radiation Oncology Considerations

General Considerations

Whole breast irradiation (WBI) is a well-established and integral component of breast conservation therapy (BCT). When given after lumpectomy, WBI has been shown to result in equivalent survival when compared to mastectomy. When compared to lumpectomy alone, the addition of radiation therapy significantly reduces the risk of local recurrence and has even been shown to improve overall survival in some patients. Conventionally fractioned WBI usually consists of treatment to doses of 45 to 50 Gy in daily doses of 1.8-2 Gy. Additional “boost” treatment to the tumor bed has been shown to further decrease the risk of local recurrence in several randomized trials, especially in younger women and those with high grade lesions.

Adjuvant radiotherapy is an important component of treatment for ductal carcinoma in situ (DCIS). Several large randomized controlled clinical trials have demonstrated the benefit of postoperative radiotherapy after excision of DCIS. These have shown a reduction in overall local recurrences and have also shown a decrease in the proportion of recurrences which are invasive. Except where otherwise noted, guidelines for breast cancer radiotherapy will also apply to patients with DCIS.

In patients treated with mastectomy for invasive breast cancer, adjuvant radiation therapy has been shown to benefit patients with high risk pathologic features including tumors greater than 5 cm, positive lymph nodes and when the surgical margin is positive. Radiotherapy may also be considered in patients with a constellation of high risk features including but not limited to tumor greater than 2 cm, extensive lymphovascular invasion and close surgical margins.

Treatment Planning

For external beam WBI, 3D conformal planning techniques are commonly used to achieve a uniform dose distribution throughout the breast. Reasonable cosmesis can be achieved and toxicity can be limited using standard wedges, electronic compensation or forward planned field-in-field segments with custom blocking. Several randomized trials of “simple IMRT” for early stage breast cancer have been reported and have shown a decrease in moist desquamation, overall cosmesis and telangiectasia when compared to 2D conventionally wedged techniques. Of note, both of these studies employed field-in-field techniques to achieve homogeneity which do not meet the CPT definition for IMRT planning and delivery.

There is evidence that radiation dose to the heart contributes to late cardiac toxicity in patients with left sided breast cancer. Gagliardi et al. have developed dose response model to predict the risk of cardiac mortality using data sets from several trials of radiotherapy for both Hodgkin’s disease and breast cancer. They predict that using the most conservative model, when the volume of heart receiving 25 Gy is less than 10% that the risk cardiac mortality from radiation is < 1% at 15 years. Whenever possible, care should be taken to exclude the heart from the primary radiation beam. Cardiac exposure can be limited through alternate patient positioning (such as the prone position) or through the use of deep inspiration breath hold technique. Limitations that would require inverse-planned IMRT or volumetric arc therapy should be rare. IMRT may be of benefit in highly selected cases where the anatomy is unfavorable or the targets closely approximate the heart, however, the use of this technology has not demonstrated a significant clinical advantage in routine cases.
Radiation to the high axilla and supraclavicular region should be considered in cases where there are involved axillary lymph nodes. Treatment of the IMN chain should be considered when those nodes are pathologically enlarged and/or PET avid on imaging studies. Inclusion of the internal mammary nodes (IMN) in the treatment field may also be indicated when there are four or more positive axillary nodes or when the primary tumor is located in the medial portion of the breast.

**Accelerated Whole Breast Irradiation (AWBI)**

There is a growing body of evidence that selected women with early stage breast cancer and favorable anatomy are suitable candidates for accelerated whole breast irradiation (AWBI). This approach has been studied in several randomized prospective clinical trials as well as a large meta-analysis. Included patients were mostly age 50 or greater, had tumors less than 4 cm, frequently did not receive chemotherapy, were generally node-negative and had a chest wall separation of < 25 cm. Patients were randomized to receive either 40-42.5 Gy in 15-16 fractions or standard radiation consisting of 50 Gy in 25 fractions. With a median follow-up of 10-12 years, there were no significant differences seen in local control, disease-free survival or overall survival. The most recent report from the UK START trials as well as the meta-analysis have demonstrated that some hypofractionated regimens yielded improved cosmetic outcome including reduced incidence of breast shrinkage, telangiectasias and breast edema in the AWBI patients compared to standard fractionation. Additional benefits of AWBI include a decrease in the number of visits for daily treatment and a reduction in the overall cost of care. These results have prompted recommendations that AWBI should be favored for the endorsed cohort and considered for other selected patients. There is evidence that administration of concurrent trastuzumab increases the risk of left ventricular dysfunction and it is unknown if this effect is more pronounced in patients treated with AWBI. For patients treated with prior chemotherapy, higher acute toxicity has been documented only in individuals whose radiotherapy began less than 20 days after chemotherapy was completed. In 2013, the American Society for Radiation Oncology (ASTRO) included AWBI as one of its featured recommendations as part of the 2013 Choosing Wisely campaign. ASTRO recently published updated consensus criteria for who should be treated with AWBI to include all age groups, any stage as long as a separate nodal field is not used, and patients who have received chemotherapy. The dose inhomogeneity exclusion has also been restated to indicated that the volume of breast tissue receiving > 105% should be minimized regardless of dose-fractionation.

**Accelerated Partial Breast Irradiation (APBI)**

Although the randomized clinical trials supporting radiotherapy have relied on whole breast irradiation, the majority of the benefit came from reducing recurrence in and immediately adjacent to the lumpectomy site. This observation has prompted investigation of whether local radiation, delivered only to the tumor bed and immediately adjacent tissue, could achieve similar results in selected patients. Accelerated partial breast irradiation (APBI) describes the treatment of the tumor bed alone with an accelerated treatment delivery schedule. Treatment can be given with brachytherapy delivered via implanted single or multilumen catheters, with external beam radiotherapy or with intraoperative radiotherapy given at the time of surgery.

A large cohort of patients who received APBI using the MammoSite applicator have been studied and the 5-year actuarial rate of ipsilateral breast tumor recurrence was 3.8%. More than 90% of patient in this study reported good to excellent cosmesis. Long term high quality data for APBI is currently lacking. The NSABP B-39/RTOG 0413 trial is a prospective, phase 3 trial which randomized patients to whole breast irradiation versus APBI. The study allowed the APBI to be delivered via brachytherapy or with 3D conformal techniques. Although the results of the study have not been published, a preliminary report of toxicity in the 3D conformal arm was reported in abstract form at the 2011 ASCO meeting. Of the 1,386 patients treated with 3D conformal APBI, there were less than 12% with grade 2 toxicity and less than 3% with grade 3 toxicity. In a conflicting report, Canadian investigators comparing WBI with 3D conformal APBI have recently published a report of adverse cosmetic outcomes seen in the RAPID trial. They found that 29% of 3D conformal APBI patients had adverse cosmetic outcomes versus 17% for WBI patients. Until further data are available regarding efficacy and safety are available, the use of 3D conformal or IMRT techniques to deliver APBI are considered not medically necessary.

Intraoperative radiotherapy (IORT) is a form of APBI in which the entire partial breast treatment is delivered at the time of lumpectomy. Several systems have been approved to deliver treatment with either electrons or 50 kV x-rays. Two large randomized trials of this approach have been published. The ELIOT trial compared electron-based IORT to WBI in women 48 years or older and tumors less than 2.5 cm. For all patients, the ipsilateral breast tumor recurrence rate was 4.4% for the IORT patients vs 0.4% for the WBI patients (p < 0.0001). A
subsequent subset analysis looking only patients who qualify as “suitable” for APBI using the ASTRO criteria revealed more favorable recurrence rates of 1.5% with electron IORT. Results of the TARGIT-A trial were recently updated and with a shorter median follow-up of 29 months they reported a local recurrence rate of 3.3% for IORT vs 1.3% for WBI. When only the patients treated at the time of lumpectomy are considered, the local recurrence rates were 2.1% for IORT vs 1.1% for WBI. In these patients, if high-risk features such as positive margins, extensive intraductal component, lobular histology, high grade histology, lymphovascular invasion or positive nodes were present on the final pathology, WBI was often added to the treatment. Survival was similar in both arms.

It is recommended that individuals considering APBI as an alternative to whole breast irradiation be counseled that whole breast irradiation is the more well-established treatment with documented long-term effectiveness and safety and that treatment with APBI may be associated with an increased risk of local recurrence and need for mastectomy. Society recommendations regarding patient suitability have been published, but are not all in agreement.

**Society Recommendations for AWBI**

**ASTRO –** An update to the 2011 Guideline was published in early 2018. The new recommendations support the use of AWBI for all ages, all stages when nodes will not be treated separately, and in patients who have received any type chemotherapy. The consensus was that when a boost is not given, a dose of 40 Gy in 15 fractions or 42.5 Gy in 16 fractions is favored. In homogeneity greater that 107% in the central axis is no longer an exclusion. The panel recommended that the volume of tissue receiving >105% should be minimized irrespective of dose schedule.

**Society Recommendations for APBI**

The National Comprehensive Cancer Network® (NCCN, 2019) - Guideline indicates that preliminary studies have shown that APBI may result in similar rates of local control in early breast cancer compared to WBI. They also note that cosmesis may be inferior and follow-up is limited. NCCN recommends treatment with APBI to be provided in a prospective clinical trial when possible. If APBI is provided off trial, then brachytherapy is recommended for those with a low risk of recurrence. They cite the ASTRO criteria for suitable candidates for APBI.

ASTRO - An update to the Evidence-Based Consensus statement was published in 2017. There were several changes in the criteria for who are “suitable” candidates for APBI. The age for the suitable group was lowered to 50 or older. The criteria were also broadened to include ductal carcinoma in situ (DCIS). The criteria are summarized below:

- Age > 50 years
- Surgical margins > 2 mm for invasive ductal cancer and > 3 mm for DCIS
- Size < 2 cm for invasive ductal cancer and < 2.5 cm for DCIS
- DCIS must be low to intermediate grade and non-palpable
- No lymphovascular invasion
- ER positive
- No invasive lobular cancer

**American College of Breast Surgeons** - The American Society of Breast Surgeons recommends the following selection criteria when considering patients for treatment with APBI, as a sole form of radiation therapy in lieu of whole breast irradiation:

- Age 45 years old or older for invasive cancer and age 50 years or older for DCIS
- Invasive carcinoma or ductal carcinoma in situ
- Total tumor size (invasive and DCIS) less than or equal to 3 cm in size
- Negative microscopic surgical margins of excision
Radiation Oncology Indications

2D or 3D Conformal is appropriate for breast cancer when ANY one of the following conditions are met:

- As an adjunct to surgical treatment after lumpectomy for localized breast cancer or DCIS
- As an adjunct to surgical treatment after mastectomy for locally advanced breast cancer
- To treat recurrent disease
- Palliative treatment of metastatic disease, including symptomatic breast or chest wall disease

Intensity Modulated Radiation Therapy (IMRT) is appropriate for breast cancer when ANY one of the following conditions are met:

- For individuals with left-sided breast lesions where the risk of cardiac exposure would be excessive with 3D conformal treatment and when ALL of the following are met:
  - 3D planning has been done, with appropriate techniques to limit toxicity
  - Despite the use of all appropriate techniques, the dose-volume constraints would lead to unacceptable risk of cardiac toxicity such that greater than 10% of the heart would receive 25 Gy or more (V25 > 10%)
  - IMRT plan demonstrates a reduction in the volume of heart receiving 25 Gy by at least 20% when compared to the 3D plan
- For individuals who will receive internal mammary node irradiation based on any one of the following:
  - Pathologically enlarged (as reported based on imaging technique utilized) internal mammary lymph node(s) by CT, MRI, PET/CT, or CXR
  - Pathologically involved internal mammary lymph node(s) (based on aspiration cytology or tissue biopsy pathology)
  - For individuals at high risk of internal mammary lymph node involvement based on any one of the following:
    - Four or more positive axillary lymph nodes
    - Medial quadrant tumor with at least one positive axillary lymph node
    - Medial quadrant T3 tumor
- For individuals where the 3D conformal plan results in hot spots (> 2 cm³) receiving more than to 110% of the prescription dose despite the use of forward planned field-in-field blocking and/or mixed beam energy (6 MV and 10 MV/15 MV)
- To treat a previously irradiated field

Note: “Forward planning IMRT” is a term used to describe field-in-field 3D conformal radiation therapy, and should not be reviewed under IMRT constraints.

Brachytherapy is appropriate for breast cancer only when used to deliver ANY one of the following:

- Intraoperative radiation therapy (IORT) is appropriate only for individuals who meet all of the following criteria:
  - Age 50 or greater
  - Tumor less than or equal to 3 cm with grossly uninvolved surgical margins
  - Lymph nodes are grossly negative and negative on intraoperative frozen section if performed
  - Distance between the edge of the applicator and the skin will be at least 6 mm
Accelerated partial breast irradiation (APBI) is appropriate only for individuals who meet all of the following criteria:

- Age 45 or greater for invasive disease or greater than 50 for DCIS
- Tumor less than or equal to 3 cm with pathologically negative surgical margins
- Lymph nodes are negative or show only immunohistochemical involvement, N0 or N0(i+)
- Distance between the edge of the applicator and the skin is at least 6 mm

Note: If intraoperative radiotherapy was used at the time of surgery but the final pathologic evaluation reveals indications for whole breast irradiation, the IORT will be considered the boost portion of the treatment.

**Fractionation**

**Whole breast irradiation (WBI)** – 17 to 28 fractions of WBI are appropriate only for individuals who meet ANY one of the following criteria:

- Lymph node involvement requiring treatment the supraclavicular or internal mammary nodal regions.
- Mastectomy or breast reconstruction have been performed
- Treatment will be delivered with 3D conformal radiotherapy and the treatment plan results in dose inhomogeneity of greater than 7% in the central axis (for example, if the plan is normalized to 95%, the maximum dose is greater than 112%)
- Concurrent chemotherapy will be administered (does not include trastuzumab or endocrine therapy)

For patients not meeting one of these criteria, up to 16 fractions of WBI are medically necessary

**Breast boost irradiation**

- An additional boost of up to 8 fractions is appropriate when the individual has fulfilled the above criteria for 17-28 fractions of WBI.
- For individuals not meeting the above criteria, an additional boost of up to 5 fractions is appropriate.

More than 36 fractions, including whole breast irradiation and boost irradiation, are not medically necessary.

**Accelerated partial breast irradiation (APBI)** delivered with up to 10 fractions delivered twice daily. More than 10 fractions are not medically necessary.

**Intraoperative radiation therapy (IORT)** is given as a single fraction. More than one fraction is not medically necessary.

**Coding**

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.
2D and 3D Conformal

**CPT/HCPCS**

77295 3-dimensional radiotherapy plan, including dose-volume histograms (3D Conformal treatment plan)

77402 Radiation treatment delivery, >1 MeV; simple.

77407 Radiation treatment delivery, >1 MeV; intermediate.

77412 Radiation treatment delivery, >1 MeV; complex.

G6003 Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 MeV

G6004 Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 MeV

G6005 Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 MeV

G6006 Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 MeV or greater

G6007 Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5 MeV

G6008 Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10 MeV

G6009 Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19 MeV

G6010 Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20 MeV or greater

G6011 Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 MeV

G6012 Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV

G6013 Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV

G6014 Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater

**Intensity Modulated Radiation Therapy (IMRT)**

**CPT/HCPCS**

77301 Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (IMRT treatment plan)

77338 Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

77385 Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking when performed; Simple (includes breast cancer, prostate cancer and compensator-based IMRT)

G6015 Intensity modulated Treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session

G6016 Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session

**Brachytherapy**

**CPT**

19296 Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes image guidance

19297 Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes image guidance

19298 Placement of radiotherapy afterloading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following partial mastectomy, includes image guidance
3-dimensional radiotherapy plan, including dose-volume histograms (3D conformal treatment plan)  
Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)  
Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)  
Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)  
Special medical radiation physics consultation  
Special treatment procedure  
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel  
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels  
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels  
Interstitial radiation source application; complex, includes supervision, handling, loading of radiation source, when performed

### Intraoperative Radiation Therapy (IORT)

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77424</td>
<td>Intraoperative radiation treatment delivery, x-ray, single treatment session</td>
</tr>
<tr>
<td>77425</td>
<td>Intraoperative radiation treatment delivery, electrons, single treatment session</td>
</tr>
<tr>
<td>77469</td>
<td>Intraoperative radiation treatment management</td>
</tr>
<tr>
<td>19294</td>
<td>Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with partial mastectomy (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

### All modalities

<table>
<thead>
<tr>
<th>ICD-10 Diagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>C50.011-C50.929</td>
</tr>
<tr>
<td>C79.81</td>
</tr>
<tr>
<td>D05.00 - D05.92</td>
</tr>
</tbody>
</table>

### References


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Central Nervous System Cancers: Intracranial, Spinal, Ocular, and Neurologic Indications

General Information

Commonly Used Modalities

- Internal Radiation Therapy (Brachytherapy)
- External Beam Radiation Therapy
  - 2D and 3D conformal
  - Intensity Modulated Radiation Therapy (IMRT)
  - Stereotactic Body Radiation Therapy (SBRT)
  - Stereotactic Radiosurgery (SRS)

Proton Beam Radiation Therapy – see separate guideline

Radiation Oncology Considerations

Brain metastasis is the most common CNS malignancy. Patients with brain metastasis have a poor prognosis, with a median survival of 2 to 3 months when treated with steroids alone. The addition of whole brain radiation therapy (WBRT) generally extends median survival to 3 to 6 months. Individual results vary significantly based on the number of metastatic lesions, the performance status of the patient and the extent of extracranial disease. In recent years, there has been a trend away from the use of WBRT in patients with limited disease who are candidates for surgery or radiosurgery in order to minimize the neurocognitive complications of WBRT.

Whole brain radiation therapy with standard 2D or 3D conformal radiation therapy is recommended for individuals with multiple brain metastases (greater than 4 treated in a given session), and should also be considered in individuals with brain metastases and any of the following: ECOG performance status greater than 2, presence of progressive and symptomatic visceral disease, or metastases significantly progressing after multiple treatment options. The RTOG has studied several different fractionation schedules for WBRT and prolongation of fractionation schedules did not improve outcomes compared to 30 Gy in 10 fractions.

A 2019 evidence-based review by the Congress of Neurological Surgeons on the role of whole brain radiotherapy recommends a dose of 30 Gy in 10 fractions to improve progression-free survival in patients with more than four metastases. To minimize the neurocognitive toxicity, local therapy in the form of surgery or stereotactic radiosurgery is recommended for patients with four or fewer accessible lesions. When WBRT is used, 6 months of memantine therapy should be offered to potentially delay, lessen or prevent the associated neurologic toxicity. The use of hippocampal avoidance has been suggested to spare neurocognitive toxicity based on a single arm phase II trial comparing outcomes to historical controls. Several randomized controlled studies of hippocampal sparing are ongoing (NCT02360215, NCT02635009).

Historically, surgical resection has been performed in patients with solitary metastasis in accessible locations. Postoperative WBRT has been shown to reduce the risk of recurrence in a randomized trial. For brain metastases greater than 4 cm in diameter or causing mass effect, surgery is preferred over stereotactic radiosurgery.

External beam radiation treatment is a common treatment for primary brain tumors as either definitive or adjuvant therapy after resection. For high grade gliomas, concurrent temozolomide chemotherapy is generally recommended as it has been shown to increase survival compared to radiotherapy alone. In 2016, ASTRO published an evidence-based clinical practice guideline on radiation therapy for glioblastoma. For patients with reasonable performance status up to age 70, a dose of 60 Gy in 30 fractions should be given. For elderly patients, hypofractionated treatment such as 40 Gy in 15 fractions gives similar results. IMRT may provide better coverage for primary brain lesions, with decreased exposure of normal brain tissue. IMRT is
recommended when a lesion is in close proximity to a critical or sensitive structure and 3D conformal radiation would result in unsafe exposure to these structures. The use of IMRT for hippocampal sparing is under active investigation and should only be used in the context of a clinical trial. IMRT is considered medically necessary in any case of repeat irradiation of overlapping or bordering treatment fields.

SRS has an excellent safety profile for many clinical situations when targets are localized, and it has applications for both benign and malignant lesions. It also often represents an alternative to surgical intervention when patients are not optimal surgical candidates. SRS has been extensively studied in the treatment of limited brain metastases. Control rates of approximately 90% are reported. Although recurrence elsewhere in the brain is common, the addition of WBRT to SRS does not improve survival. This has led to the ASTRO Choosing Wisely recommendation not to routinely add WBRT to SRS for limited brain metastasis. SRS is not recommended for the treatment of CNS lymphoma.

Stereotactic boost for high grade gliomas has been studied in several randomized controlled clinical trials. RTOG 93-05 randomized patients with glioblastoma multiforme to upfront SRS followed by conventional radiotherapy and carmustine to the same treatment without SRS. With a median follow-up of 61 months, there was no difference in survival, pattern of failure or quality of life in the two groups. RTOG 0023 studied the use of a stereotactic conformal boost for supratentorial glioblastoma multiforme. In this study, four weekly stereotactic boost treatments were delivered to give a cumulative dose of 70-78 Gy to the postoperative enhancing tumor. There was no difference in survival compared to historical controls. Based on these studies, SRS or SBRT are considered investigational for the primary treatment of grade 3-4 gliomas.

For certain benign CNS abnormalities, SRS has been shown to be a safe and effective treatment. Soon after the development of the Gamma Knife by Leksell in the 1970s, it was studied for the treatment of arteriovenous malformations (AVM) where it has been shown to have an 80% obliteration rate. Based on this proof of concept, SRS has subsequently been shown to be an effective alternative to surgery for a wide variety of benign lesions including ocular melanoma, retinoblastoma, schwannoma, craniopharyngioma, pineal lesions and pituitary adenoma. SRS for the treatment of trigeminal neuralgia is medically necessary in cases refractory to medical management. SRS for the treatment of epilepsy, Parkinson’s disease and other movement disorders is listed as “insufficient evidence” in an evidence-based review by the American Academy of Neurology and therefore remains investigational at this time.

SRS is given as a single fraction. Cranial stereotactic treatment given in 2-5 fractions is billed as SBRT.

For metastatic lesions outside the brain, please refer to specific guidelines for the appropriate location (e.g., Lung Cancer for lung metastases).

## Radiation Oncology Indications

### 2D or 3D Conformal is appropriate for CNS cancers when ANY of the following conditions are met

- Primary cranial, spinal, and ocular lesions OR
- Metastatic cranial, spinal, and ocular lesions OR
- Prophylactic cranial irradiation

### Intracranial Lesions

#### Primary Malignant Brain Lesions

**High Grade Gliomas (grade 3-4)**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for high grade gliomas in individuals with good performance status (based on either of the following)

- ECOG 0, 1, or 2 OR
- Karnofsky Scale greater than or equal to 70% AND

When one of the following conditions is met:
The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure OR

To treat a previously irradiated field

**Stereotactic Radiosurgery (SRS)** is appropriate for high grade gliomas in individuals with good performance status (based on either of the following)

- ECOG 0, 1, or 2 OR
- Karnofsky Scale greater than or equal to 70% AND

When one of the following conditions is met:

- Recurrent disease OR
- To treat a previously irradiated field

**Low Grade Gliomas (grade 1-2)**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for low grade gliomas in individuals with good performance status (based on either of the following)

- ECOG 0, 1, or 2 OR
- Karnofsky Scale greater than or equal to 70% AND

When one of the following conditions is met:

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure OR
- To treat a previously irradiated field

**Stereotactic Radiosurgery (SRS)** is appropriate for low grade gliomas in individuals with good performance status (based on either of the following)

- ECOG 0, 1, or 2 OR
- Karnofsky Scale greater than or equal to 70% AND

When one of the following conditions is met:

- Initial treatment OR
- Recurrent disease OR
- To treat a previously irradiated field

**Medulloblastoma supratentorial primitive neuroectodermal tumors (PNET)**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for medulloblastoma, supratentorial, PNET, ependymoma when ANY of the following conditions are met

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure OR
- In a pediatric patient, age less than 21 OR
- To treat a previously irradiated field

**Stereotactic Radiosurgery (SRS)** is appropriate for medulloblastoma, supratentorial PNET, ependymoma when the following condition is met

- Only to treat a previously irradiated field

**CNS lymphoma**
Intensity Modulated Radiation Therapy (IMRT) is appropriate for CNS lymphoma when **ANY of the following conditions are met**

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure **OR**
- To treat a previously irradiated field

Stereotactic Radiosurgery (SRS) is appropriate for CNS lymphoma when the following condition is met:
- Only to treat a previously irradiated field

**Metastatic Brain Lesions**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for metastatic brain lesions in individuals with good performance status (**based on either of the following**)

- ECOG 0, 1, or 2 **OR**
- Karnofsky Scale greater than or equal to 70% **AND**

When one of the following conditions is met

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem, and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure **OR**
- To treat a previously irradiated field

Stereotactic Radiosurgery (SRS) is appropriate for metastatic brain lesions **when ANY of the following conditions are met**

- For individuals with good performance status (**based on either of the following**)
  - ECOG 0, 1, or 2 **OR**
  - Karnofsky Scale greater than or equal to 70% **AND**
- To treat a previously irradiated field

**Benign Brain Lesions**

**Intracranial arteriovenous malformations (AVMs)**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for AVMs when the following condition is met

- Only to treat a previously irradiated field

Stereotactic radiosurgery (SRS) is appropriate for AVMs when the following condition is met

- For treatment of intracranial arteriovenous malformations

**Pituitary adenomas**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for pituitary adenomas **when ANY of the following conditions are met**

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, or optic chiasm, and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure **OR**
- To treat a previously irradiated field

Stereotactic radiosurgery (SRS) is appropriate for pituitary adenomas **when ANY of the following conditions are met**

- When individual is symptomatic **OR**
- To treat a previously irradiated field

**Meningioma**
Intensity Modulated Radiation Therapy (IMRT) is appropriate for meningioma when **ANY of the following conditions are met**

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem, and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure **OR**
- To treat a previously irradiated field

Stereotactic radiosurgery (SRS) is appropriate for meningioma when **ANY of the following conditions are met**

- When lesion is unresectable or recurrent, or if there is residual disease following surgery **OR**
- To treat a previously irradiated field

**Other benign brain tumors: acoustic neuromas, craniopharyngiomas, pineal gland tumors, schwannomas**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for other benign brain tumors when **ANY of the following conditions are met**

- The lesion falls near a critical structure, such as the optic nerve, lens, retina, optic chiasm, cochlea, or brainstem and standard techniques such as 3D conformal radiotherapy would result in significant risk of damage to the critical structure **OR**
- To treat a previously irradiated field

Stereotactic radiosurgery (SRS) is appropriate for other benign brain tumors when the following condition is met

- For treatment of other benign brain tumors, including acoustic neuromas, craniopharyngiomas, pineal gland tumors, schwannomas

**Ocular Lesions**

**Uveal Melanoma**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for uveal melanoma when the following condition is met

- Only to treat a previously irradiated field

Stereotactic Radiosurgery (SRS) is appropriate for uveal melanoma when **ANY of the following conditions are met**

- For treatment of melanoma of the choroid **OR**
- To treat a previously irradiated field

Brachytherapy is appropriate for uveal melanoma when **ALL of the following conditions are met**

- When apical height of the tumor is up to 10.0 mm **AND**
- The maximal base diameter is 18.0 mm or less

**Retinoblastoma**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for retinoblastoma when **ANY of the following conditions are met**

- In pediatric individuals (age less than 21) **OR**
- To treat a previously irradiated field

Brachytherapy is appropriate for retinoblastoma when **ALL the following conditions are met**

- When apical height of the tumor is up to 10.0 mm **AND**
- The maximal base diameter is 18.0 mm or less
Spine Lesions; Primary or Metastatic Lesions of the Spine

Intensity Modulated Radiation Therapy (IMRT) is appropriate for spine lesions when the following condition is met:

- Only to treat a previously irradiated field

Stereotactic Body Radiation therapy (SBRT) is appropriate for spine lesions when either of the following conditions is met

- When other treatment options are not available (both must be met)
  - Not amenable to surgical resection (at least one must apply)
    - Related to prior surgery, tumor location, or surgical candidacy OR
    - Surgery alone is not an option AND
  - When lesions are not amenable to 3D conformal techniques OR
- To treat a previously irradiated field

Note: When SRS/SBRT is being requested to treat a patient with oligometastatic disease with potentially curative intent, please refer to separate criteria in the Oligometastatic Extracranial Disease section of the Guidelines.

Other Neurologic Conditions; Trigeminal Neuralgia

Intensity Modulated Radiation Therapy (IMRT) is appropriate for trigeminal neuralgia when the following condition is met

- To treat a previously irradiated field

Stereotactic radiosurgery (SRS) is appropriate for trigeminal neuralgia when ANY of the following conditions are met

- When symptoms are refractory to standard medical management OR
- To treat a previously irradiated field

Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

3D Conformal

CPT

77295 ................. 3-dimensional radiotherapy plan, including dose-volume histograms

ICD-10 Diagnoses

Not specified

Intensity Modulated Radiation Therapy

CPT/HCPCS

77301 ................. Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex

Intensity modulated Treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session

Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session

ICD-10 Diagnoses

- C69.20 - C69.22... Retinoblastoma
- C69.40 - C69.42... Malignant neoplasm uveal tract
- C71.0 - C71.9... Malignant neoplasm brain
- C79.31 - C79.49... Secondary malignant neoplasm brain & spinal cord
- C85.81... CNS lymphoma
- D33.0 - D33.2... Benign brain lesions
- D35.2... Pituitary adenoma
- D35.4... Benign pineal tumor
- G50.0... Trigeminal neuralgia
- Q28.2... Intracranial AVM

Stereotactic Body Radiation Therapy

CPT/HCPCS

- 61796... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial lesion
- 61797... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, simple
- 61798... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial lesion
- 61799... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, complex
- 63620... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); one spinal lesion
- 63621... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each add’l spinal lesion
- 77295... 3-dimensional radiotherapy plan, including dose-volume histograms
- 77301... Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)
- 77338... Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
- 77373... Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
- 77370... Special medical radiation physics consultation
- 77435... Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
- 77470... Special treatment procedure
- G0339... Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
- G0340... Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

Stereotactic Radiosurgery

CPT/HCPCS

- 61796... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial lesion
- 61797... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, simple
- 61798... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial lesion
- 61799... Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, complex
61800 .................. Application of stereotactic headframe for stereotactic radiosurgery
63620 .................. Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); one spinal lesion
63621 .................. Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each add’l spinal lesion
77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms
77301 .................. Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)
77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77370 .................. Special medical radiation physics consultation
77371 .................. Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based
77372 .................. Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based
77432 .................. Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)
G0339 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
G0340 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

ICD-10 Diagnoses (SBRT/SRS)

C41.2 .................. Malignant neoplasm vertebral column
G50.0 .................. Trigeminal neuralgia
C69.30 - C69.32 … Melanoma of choroid
C71.0 - C71.9 ……… Malignant neoplasm of brain
C79.31 - C79.49 … Secondary malignant neoplasm brain & spinal cord
D33.0 - D33.2 ……. Benign brain lesions
D35.2 .................. Pituitary adenoma
D35.4 .................. Benign pineal tumor
Q28.2 .................. Intracranial AVM

Brachytherapy

CPT

67218 .................. Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions; radiation by implantation of source (includes removal of source)
77295 .................. 3-Dimensional radiotherapy plan, including dose-volume histograms \
77316 .................. Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)
77317 .................. Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)
77318 .................. Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)
77370 .................. Special medical radiation physics consultation
77470 .................. Special treatment procedure
77778 .................. Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77790 .................. Supervision, handling, loading of radiation source

ICD-10 Diagnoses (SBRT/SRS)

C69.20 - C69.22 … Retinoblastoma
C69.40 - C69.42 … Uveal melanoma
References


21. Gondi V, NRG Oncology. Whole-brain radiation therapy with or without hippocampal avoidance in treating patients with limited stage or extensive stage small cell lung cancer (NRG CC003) [Clinical Trial]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT012365009.


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer
Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Colorectal and Anal Cancers

General Information

Commonly Used Modalities

External Beam Radiation Therapy
- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Anal Cancer
Cancer of the anal region are relatively rare, accounting for less than 3% of all digestive system cancers. They are almost always squamous cell carcinomas and are frequently associated with HPV infection. Because of the lymphatic drainage of this area, the inguinal lymph nodes are at risk and are commonly involved when lesions involve the area below the dentate line. Although these cancers have been treated with abdominoperineal resection in the past, the current standard of care is concomitant chemoradiotherapy with a fluoropyrimidine and either mitomycin or cisplatin. Doses of 45 Gy are given for early stage tumors. More advanced and node positive cancers are treated to doses of 54-59.4 Gy. IMRT techniques, which can reduce the toxicity associated with radiation, are preferred over 3D conformal techniques for the treatment of anal cancer and cancers of the anal canal. The radiation field includes the pelvis, the anus, the perineum, and the inguinal lymph nodes. Definitive treatment of anal cancers typically involves concurrent radiation and chemotherapy.

Palliative radiation with 3D conformal techniques is recommended for metastatic disease or to enhance local control of a symptomatic bulky primary.

Rectal Cancer
Colorectal cancer is much more common than anal cancer and is the second most common cause of cancer death. Rectal cancers, which occur below the peritoneal reflection, benefit from radiation therapy which has been shown to reduce local recurrence and improve survival. Radiation is generally given with 5-fluorouracil or capecitabine chemotherapy. Preoperative chemoradiation is preferable because it is better tolerated and improves the chance of sphincter sparing surgery in marginally resectable patients. Precision techniques like 3D conformal radiotherapy and IMRT have been shown to reduce the dose to bowel and minimize side effects. The radiation field should include the presacral nodes, internal iliac nodes, and external iliac nodes for T4 tumors. Typically, 45 Gy is given to the initial field with an additional 5.4 – 9 Gy being given to a cone down boost field. Short-course preoperative radiotherapy to a dose of 25 Gy is another alternative.

Colon Cancer
Radiation is not a standard part of local treatment for colon cancer, but is incorporated into treatment for selected patients. It is generally used in situations where there is an elevated risk of local recurrence due to local invasion of the surrounding tissues. 3D conformal radiation is the standard option, and IMRT is reserved for repeat irradiation of previously treated patients.

Stereotactic radiation techniques have been considered in highly selected cases of limited hepatic metastases; however, surgical resection is the standard of care. Please see the section on hepatobiliary cancers for more guidance on the treatment of liver metastases.

For review of metastatic sites, please refer to specific guidelines for the appropriate location (e.g., CNS Cancers for brain metastases, Lung Cancer for lung metastases).
Radiation Oncology Indications

2D or 3D Conformal is appropriate for colorectal cancers when ANY of the following conditions are met

- Primary treatment of colon, rectal, and anal cancers (often in combination with chemotherapy) OR
- Palliation of metastatic disease, particularly to control symptoms

Anal Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for anal cancer when the following conditions are met

- Treatment of cancer of the anus and anal canal

Stereotactic Body Radiation Therapy (SBRT) is appropriate for anal cancer when the following condition is met

- Only to treat a previously irradiated field

Rectal Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for rectal cancer when the following condition is met

- Treatment of rectal adenocarcinoma

Stereotactic Body Radiation Therapy (SBRT) is appropriate for rectal cancer when the following condition is met

- Only to treat a previously irradiated field

Colon Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for colon cancer when the following condition is met

- Only to treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for colon cancer when the following condition is met

- Only to treat a previously irradiated field

Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

3D Conformal

CPT

77295 .................3-dimensional radiotherapy plan, including dose-volume histograms (3D Conformal treatment plan)

ICD-10 Diagnoses

Not specified
Intensity Modulated Radiation Therapy

CPT/HCPCS

77301 .................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (Listed once only)
77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77386 .................. Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex
G6015 .................. Intensity modulated Treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
G6016 .................. Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session

ICD-10 Diagnoses

C18.0 - C18.9........ Malignant neoplasm of colon
C19 - C21.8........ Malignant neoplasm rectum, rectosigmoid junction & anus
Z92.3.............. Personal history of irradiation

Stereotact ic Body Radiation Therapy

CPT/HCPCS

77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms
77301 .................. Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)
77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77370 .................. Special medical radiation physics consultation
77373 .................. Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77435 .................. Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77470 .................. Special treatment procedure
G0339 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
G0340 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

ICD-10 Diagnoses (SBRT/SRS)

Z92.3.............. Personal history of irradiation

References


Gastrointestinal Cancers, Non-Colorectal: Cholangiocarcinoma, Esophageal, Gastric, Liver, Pancreatic

General Information

Commonly Used Modalities

Internal Radiation Therapy (Brachytherapy)

External Beam Radiation Therapy

- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Esophageal Cancer

Esophageal cancers can be histologically classified as squamous cell carcinoma or adenocarcinoma. Squamous cancers are more common in the cervical and mid-thoracic esophagus while adenocarcinomas are more common in the distal esophagus and gastroesophageal junction. The latter are more common in Western countries and are associated with gastroesophageal reflux and Barrett's esophagus. Radiation therapy is a common part of the multidisciplinary treatment of esophageal cancers. Radiation can be used preoperatively, post-operatively, as primary therapy in conjunction with chemotherapy or as a palliative modality to improve swallowing. Long-term results of the CROSS randomized controlled trial of neoadjuvant chemoradiation followed by surgery showed improved survival compared to surgery alone. Radiation in that study was given with 3D conformal techniques. IMRT is still under active investigation for treatment of esophageal cancer. Retrospective comparisons have not demonstrated improved survival but have shown a decrease in grade 3 toxicities such as hospitalization, feeding tube placement and greater than 20% weight loss. IMRT should only be used in curative cases where 3D conformal planning shows unacceptable doses to surrounding structures including the heart, lungs, spinal cord or small bowel. In these cases, a documented 3D conformal plan may be requested for review.

Gastric Cancer

Gastric cancer is relatively uncommon in the United States but is a common cause of cancer and cancer mortality worldwide. It is associated with Helicobacter pylori infection, smoking and heavy drinking. Gastric cancer frequently presents at an advanced stage. Chemoradiation has an established role in the adjuvant treatment of resected tumors based on the results of intergroup study 0116. Patients in that randomized study who received chemoradiation had improved survival compared to patients treated with surgery alone. Use of 3D treatment planning is recommended. Treatment recommendations depend on the location of the bulk of the tumor, location and lymph node involvement. In addition to adjuvant post-operative treatment, radiation is used in a variety of clinical situations, including preoperative treatment, in combination with chemotherapy, and as a palliative therapy. Significant supportive care is required during a full course of treatment. No prospective studies of IMRT in gastric cancer have been published. Several institutions have noted improved dose distribution and better organ sparing with IMRT for stomach cancer. No survival advantage with IMRT has been reported.

Hepatobiliary Cancer

Hepatocellular carcinoma (HCC) and cholangiocarcinomas of the gallbladder, intrahepatic and extrahepatic bile ducts are relatively rare but lethal cancers of the liver and bile ducts. HCC is commonly associated with cirrhosis
due to hepatitis and other factors. Although there are no prospective data on the use of IMRT for the treatment of these cancers, the liver is very sensitive to radiation therapy and IMRT may have a limited role in the treatment of HCC and cholangiocarcinoma when 3D conformal therapy would result in unacceptable toxicity due to exposure of the liver and other surrounding normal tissues. There is growing literature support for the use of SBRT as a local treatment option for hepatocellular cancer. This technology remains under active investigation in many clinical situations, and more data is needed to clarify the role of SBRT. Patients should first be evaluated for potential curative therapy, such as resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE) or transplantation.

Selective Internal Radiation Therapy (SIRT) is also known as radioembolization. This technique targets the delivery of small beads or microspheres containing yttrium-90 to the tumor. It is used for palliation of liver tumors, and is sometimes used as a bridge to liver transplantation.

**Liver Metastases**

The use of stereotactic techniques to treat liver metastases is the subject of clinical trials. Small trials have addressed this issue, but long term survival and quality of life remain unclear.

**Pancreatic Cancer**

For the treatment of pancreatic cancer, radiation is recommended in the setting of unresectable or borderline resectable disease (neoadjuvant or definitive), adjuvant treatment after surgery, and palliation of symptoms. Outside of palliative care, radiation is traditionally administered concurrently with chemotherapy. There is no clear standard for neoadjuvant therapy, and multiple chemoradiotherapy options are available. 3D conformal radiation techniques are considered standard. A recent systematic review by Bittner compares outcomes and toxicity in patients treated with IMRT and 3D conformal radiotherapy for pancreatic adenocarcinoma. There were no apparent differences in overall or progression free survival. Both nausea/vomiting and diarrhea were statistically lower with IMRT compared to 3D conformal, although the differences were modest (7.8% vs 13% and 2% vs 11.6% respectively, p<0.001 for both). Long term grade 3 or greater GI toxicity was 5% with IMRT vs 10.6% with 3D (p=0.017). Given the lack of improved outcomes, IMRT should only be used in curative cases where 3D conformal planning would result in unacceptable doses to surrounding normal tissues. Care should be taken to adhere to recommended target coverage and dose specifications as radiation quality has been shown to impact survival in several studies.

Initial experience with single fraction SBRT for unresectable pancreatic cancer resulted in favorable local control rates but high rates of late gastrointestinal complications. Subsequent studies using fractionated SBRT have shown lower rates of late toxicity. A recent retrospective review of locally advanced pancreatic cancer cases in the National Cancer Database (NCDB) compared outcomes between 7,819 patients treated with conventional radiation with outcomes in 631 patients treated with SBRT. Two year overall survival was 16.3% with conventional radiation versus 20.3% in patients treated with SBRT (p<0.001). This benefit was maintained in the propensity matched analysis. Another retrospective study compared outcomes in the NCDB between chemo alone, chemo plus EBRT, chemo plus IMRT and chemo plus SBRT. Median overall survival results were 9.9 months, 10.9 months, 12 months and 13.9 months respectively. For the match propensity cohort, overall survival was superior with SBRT versus chemotherapy alone (p<0.018). SBRT is considered medically necessary for the treatment of locally advanced, non-metastatic adenocarcinoma of the pancreas.

For review of other metastatic sites, please refer to specific guidelines for the appropriate location (e.g. CNS for brain metastases, Lung for lung metastases).

**Radiation Oncology Indications**

2D or 3D conformal is appropriate when ANY of the following conditions are met

- Primary disease, with or without chemotherapy OR
- Metastatic disease, particularly for palliation of symptoms
Cholangiocarcinoma

Intensity Modulated Radiation Therapy (IMRT) is appropriate for curative treatment of cholangiocarcinoma when EITHER of the following conditions is met

- Where risk of critical structure exposure would be excessive with 3D conformal treatment (both must be met)
  - 3D planning has been done with appropriate techniques to limit toxicity, but organ at risk limits have been exceeded (based on QUANTEC limits*) AND
  - IMRT demonstrates improvement to tissue exposure to within safe ranges OR
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for cholangiocarcinoma when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for cholangiocarcinoma when the following condition is met

- As adjuvant treatment after surgery for individuals with ANY of the following:
  - R1 resection (positive margin) OR
  - R2 resection (gross residual disease after resection) OR
  - Carcinoma in situ found at the surgical specimen margin

Esophageal Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for the curative treatment of esophageal cancer when EITHER of the following conditions is met

- Where risk of critical structure (heart, lung) exposure would be excessive with 3D conformal treatment (both must be met)
  - 3D planning has been done with appropriate techniques to limit toxicity, but organ at risk limits have been exceeded (based on QUANTEC limits*) AND
  - IMRT demonstrates improvement to tissue exposure to within safe ranges OR
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for esophageal cancer when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for esophageal cancer when ANY of the following conditions are met

- To treat a gross residual tumor or unresectable luminal lesion OR
- For palliative treatment of an obstructing tumor

Gastric Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for curative treatment of gastric cancer when EITHER of the following conditions is met

- Where risk of critical structure exposure would be excessive with 3D conformal treatment (both must be met)
  - 3D planning has been done with appropriate techniques to limit toxicity, but organ at risk limits have been exceeded (based on QUANTEC limits*) AND
  - IMRT demonstrates improvement to tissue exposure to within safe ranges OR
- To treat a previously irradiated field
Stereotactic Body Radiation Therapy (SBRT) is appropriate for gastric cancer when the following condition is met
- Only to treat a previously irradiated field

Liver Cancer

Hepatocellular carcinoma

Intensity Modulated Radiation Therapy (IMRT) is appropriate for the curative treatment of liver cancer when either of the following conditions is met
- Where risk of critical structure exposure would be excessive with 3D conformal treatment (both must be met)
  - 3D planning has been done with appropriate techniques to limit toxicity, but organ at risk limits have been exceeded (based on QUANTEC limits*) AND
  - IMRT demonstrates improvement to tissue exposure to within safe ranges OR
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate when any of the following conditions are met
- As palliative treatment for individuals with liver-related symptoms OR
- As treatment of up to 3 lesions, as an option to surgery or embolization when these therapies have been done and have failed, or are contraindicated, when all of the following conditions are met
  - Diameter less than 6 cm AND
  - Patients with Child-Pugh category A or B AND
    - Note: SBRT has not been established as a safe treatment option in patients with Child-Pugh category C cirrhosis
  - Individual has a good performance status (ECOG 0-2, Karnofsky 70% or greater) OR
- To treat a previously irradiated field

Liver Metastases

Intensity Modulated Radiation Therapy (IMRT) is appropriate for liver metastases when the following condition is met
- Only to treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for liver metastases when any of the following conditions are met
- As palliative treatment for individuals with liver-related symptoms OR
- To treat a previously irradiated field

Pancreatic Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for the curative treatment of pancreatic cancer when either of the following conditions is met
- Where risk of critical structure exposure would be excessive with 3D conformal treatment (both must be met)
  - 3D planning has been done with appropriate techniques to limit toxicity, but organ at risk limits have been exceeded (based on QUANTEC limits*) AND
  - IMRT demonstrates improvement to tissue exposure to within safe ranges OR
- To treat a previously irradiated field
Stereotactic Body Radiation Therapy (SBRT) is appropriate for pancreatic cancer **when EITHER of the following conditions is met**

- To treat locally advanced or recurrent disease without evidence of distant metastasis **OR**
- To treat a previously irradiated field

*QUANTEC limits*

- Lung: V20 ≤ 30%
- Heart: V25 ≤ 10%
- Pericardium: Mean dose ≤ 26 Gy OR V30 < 46%
- Spinal Cord: Mean dose ≤ 45 Gy OR Maximum dose 50 Gy
- Esophagus: Mean dose < 34 Gy
- Small bowel: Dmax < 54 Gy
- Liver: Mean dose < 30 Gy
- Kidney: Mean dose < 18 Gy. If one kidney, < 15% to receive 18 Gy

**Coding**

*3D Conformal*

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
</tbody>
</table>

**ICD-10 Diagnoses**

Not specified

*Intensity Modulated Radiation Therapy*

<table>
<thead>
<tr>
<th>CPT/HPCPS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77301</td>
<td>Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications</td>
</tr>
<tr>
<td>77338</td>
<td>Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan</td>
</tr>
<tr>
<td>77386</td>
<td>Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex</td>
</tr>
<tr>
<td>G6015</td>
<td>Intensity modulated Treatment delivery, single or multiple fields/arc, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session</td>
</tr>
<tr>
<td>G6016</td>
<td>Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session</td>
</tr>
</tbody>
</table>

**ICD-10 Diagnoses**

- C15.3 - C15.9......Malignant neoplasm esophagus
- C16.0 - C16.9......Malignant neoplasm stomach
- C22.0..............Hepatocellular carcinoma
C22.1 Cholangiocarcinoma
C24.0 Malignant neoplasm extrahepatic bile ducts
C25.0 - C25.9 Malignant neoplasm pancreas
C78.7 Secondary malignancy, liver
Z92.3 Personal history of irradiation

**Stereotactic Body Radiation Therapy**

**CPT/HCPCS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77301</td>
<td>Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)</td>
</tr>
<tr>
<td>77338</td>
<td>Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77373</td>
<td>Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77435</td>
<td>Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77470</td>
<td>Special treatment procedure</td>
</tr>
<tr>
<td>G0339</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment</td>
</tr>
<tr>
<td>G0340</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment</td>
</tr>
</tbody>
</table>

**ICD-10 Diagnoses (SBRT/SRS)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C22.0</td>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>C78.7</td>
<td>Secondary malignancy, liver</td>
</tr>
<tr>
<td>Z51.5</td>
<td>Encounter for palliative care</td>
</tr>
<tr>
<td>Z92.3</td>
<td>Personal history of irradiation</td>
</tr>
</tbody>
</table>

**Brachytherapy**

**CPT**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77316</td>
<td>Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)</td>
</tr>
<tr>
<td>77317</td>
<td>Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)</td>
</tr>
<tr>
<td>77318</td>
<td>Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77470</td>
<td>Special treatment procedure</td>
</tr>
<tr>
<td>77761</td>
<td>Intracavitary radiation source application; simple</td>
</tr>
<tr>
<td>77762</td>
<td>Intracavitary radiation source application; intermediate</td>
</tr>
<tr>
<td>77763</td>
<td>Intracavitary radiation source application; complex</td>
</tr>
<tr>
<td>77770</td>
<td>Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel</td>
</tr>
<tr>
<td>77771</td>
<td>Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels</td>
</tr>
<tr>
<td>77772</td>
<td>Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels</td>
</tr>
</tbody>
</table>
ICD-10 Diagnoses

C15.3 - C15.9 .... Malignant neoplasm esophagus
C22.1 ................. Cholangiocarcinoma
C24.0 .................. Malignant neoplasm extrahepatic bile ducts
D00.1 .................. Carcinoma in-situ, esophagus

References


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Genitourinary Cancers: Bladder, Penile, and Testicular

General Information

Commonly Used Modalities

Internal Radiation Therapy (Brachytherapy)

External Beam Radiation Therapy

- 2D and 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Bladder Cancer

Bladder cancers arise in the transitional urothelium which lines the urinary bladder. About two-thirds of these do not invade the muscle layer at the time of diagnosis and are treated with transurethral resection (TURBT) with or without instillation of an intravesicle adjuvant therapy such as BCG, mitomycin or gemcitabine. Muscle invasive cancer requires more aggressive treatment. The standard of care is radical cystectomy. Postoperative radiotherapy is indicated for T3 or T4 tumors and when there is involvement of the pelvic lymphatics. Bladder preservation therapy with concurrent chemoradiotherapy is an alternative for highly motivated patients after maximal TURBT and results in 60-80% rates of functional bladder sparing. In the palliative setting, radiation alone is an effective treatment for hematuria. For definitive therapy, it is recommended to treat the whole bladder to 40-45 Gy followed by a boost to the bladder tumor to a total dose up to 66 Gy excluding, if possible, normal areas of the bladder from the boost volume. When high doses of radiotherapy are given, IMRT is often indicated to minimize the dose to pelvic organs at risk, especially the small bowel.

Penile Cancer

Penile cancer is rare and requires multidisciplinary management. Brachytherapy is the preferred approach in selected cases of early stage penile cancers. Concurrent chemoradiotherapy as primary treatment, or after surgery is recommended for larger tumors and when there is nodal involvement. Radiation may also be used when surgical margins are positive.

Testicular Cancer

Following inguinal orchietomy for early stage pure seminoma, there is an approximately 15% risk of recurrence in the para-aortic lymph nodes. External beam radiation significantly reduces this risk and is an option to surveillance or single agent chemotherapy in stage I disease. Radiation to the para-aortic and ipsilateral iliac nodes is an alternative to chemotherapy in individuals with stage IIA and IIB disease. IMRT is not recommended for treatment of pure testicular seminomas due to the low doses given and the increased risk of secondary malignancy in the kidney, liver, or bowel with IMRT. Radiation is not a standard component in the treatment of non-seminomatous testicular cancer. For review of metastatic sites, please refer to specific guidelines for the appropriate location (e.g., Central Nervous System [CNS] for brain metastases, Lung for lung metastases).

Radiation Oncology Indications

2D or 3D conformal is appropriate for genitourinary cancers when ANY of the following conditions are met

- Primary disease, with or without chemotherapy, particularly to irradiate inguinal and/or pelvic lymph nodes OR
• Metastatic disease, particularly for palliation of symptoms

Bladder Cancer
Intensity Modulated Radiation Therapy (IMRT) is appropriate for bladder cancer when the following conditions are met
• To treat primary, non-metastatic bladder carcinoma AND
• Treatment intent is curative
Stereotactic Body Radiotherapy (SBRT) is appropriate for bladder cancer when the following condition is met
• Only to treat a previously irradiated field

Penile Cancer
Intensity Modulated Radiation Therapy (IMRT) is appropriate for penile cancer when the following condition is met
• Only to treat a previously irradiated field
Stereotactic Body Radiotherapy (SBRT) is appropriate for penile cancer when the following condition is met
• Only to treat a previously irradiated field
Brachytherapy is appropriate for penile cancer when the following condition is met
• Squamous cell carcinoma, confined to the glans or prepuce when: (both must be met)
  o Tumor size is less than or equal to 4 cm AND
  o Inguinal lymph nodes are uninvolved or unable to be assessed (NO or NX)

Testicular Cancer
Intensity Modulated Radiation Therapy (IMRT) is appropriate for testicular cancer when the following condition is met
• Only to treat a previously irradiated field
Stereotactic Body Radiotherapy (SBRT) is appropriate for testicular cancer when the following condition is met
• Only to treat a previously irradiated field

Coding
CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

3D Conformal
CPT
77295 3-dimensional radiotherapy plan, including dose-volume histograms

ICD-10 Diagnoses
Not specified
Intensity Modulated Radiation Therapy

CPT/HCPCS

77301.................Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications
77338.................Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77386.................Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex
G6015.................Intensity modulated Treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
G6016.................Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session

ICD-10 Diagnoses

C67.0 - C67.9........Malignant neoplasm bladder
Z92.3..............Personal history of irradiation

Stereotactic Body Radiation Therapy

CPT/HCPCS

77295.................3-dimensional radiotherapy plan, including dose-volume histograms
77301.................Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Listed once only)
77338.................Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77370.................Special medical radiation physics consultation
77373.................Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77435.................Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77470.................Special treatment procedure
G0339.................Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
G0340.................Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

ICD-10 Diagnoses (SBRT/SRS)

Z92.3..............Personal history of irradiation

Brachytherapy

CPT

77295.................3-dimensional radiotherapy plan, including dose-volume histograms
77316.................Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)
77317.................Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)
77318.................Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)
77370.................Special medical radiation physics consultation
77470.................Special treatment procedure
77761.................Intracavitary radiation source application; simple
77762.................Intracavitary radiation source application; intermediate
77763.................Intracavitary radiation source application; complex
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel

Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, performed; 2-12 channels

Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels

Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed

ICD-10 Diagnoses

C60.0 - C60.9......Malignant neoplasm penis & other male genital organs

References


Gynecologic Cancers: Cervical, Fallopian Tube, Ovarian, Uterine, and Vulvar/Vaginal

General Information

Commonly Used Modalities

Internal Radiation Therapy (Brachytherapy)

External Beam Radiation Therapy

- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Brachytherapy is considered standard of care in the treatment of many gynecologic malignancies, and both high dose rate (HDR) and low dose rate (LDR) brachytherapy treatments are used.

External beam radiation is used in many clinical situations to treat pelvic tissues and regional lymph nodes. With significant toxicity constraints, particularly gastrointestinal and urologic toxicity, IMRT is often the recommended modality.

IMRT is not routinely recommended for palliative treatment of symptoms in the setting of advanced disease.

Cervical Cancer

In the United States, cervical cancer is relatively uncommon. About 80% of cases are squamous cell carcinoma. Human papilloma virus (HPV) infection is known to increase the risk of cervical cancer and this had led to development of a vaccine to prevent the disease. Early stage cervical cancer can be treated with either surgery or radiation. More advanced disease is treated with concurrent chemoradiotherapy followed by brachytherapy. If high risk features are found at the time of surgery, adjuvant postoperative radiotherapy is indicated. IMRT is helpful in minimizing radiation dosage to the critical structures in the pelvis, particularly the bowel. Compared to 3D conformal radiotherapy, IMRT has been shown to reduce the incidence of acute and chronic gastrointestinal side effects and also lower the risk of bowel obstruction.

External beam radiation techniques should not be considered alternatives to brachytherapy for an intact cervix.

Brachytherapy is commonly incorporated into the definitive management of cervical cancer. For treatment of the intact cervix, tandem and ovoid or tandem and ring applicators are most often used. For more advanced cases, interstitial implants may be required. Brachytherapy can be delivered with either low dose rate (LDR) or high dose rate (HDR) techniques. When LDR brachytherapy is used, two applications are typically performed. For HDR treatment, up to six fractions are appropriate. Brachytherapy can be used alone for very early stage cervical cancer. More commonly, brachytherapy is used as a boost following external beam radiotherapy. When tumors are not adequately dosed with brachytherapy, completion hysterectomy may be of benefit. Concurrent platinum based chemotherapy has been shown to improve survival compared to radiotherapy alone for early stage high risk disease as well as advanced stage disease.

Uterine Neoplasms

Endometrial cancers arise in the uterine lining and commonly present as post-menopausal bleeding. They are more common than cervical cancer with approximately 55,000 cases per year. The primary treatment for endometrial cancer is surgery. Primary radiation can be used in patients who are not surgical candidates. Adjuvant radiation therapy has been shown to decrease recurrences in women at risk. Risk factors for recurrence include age, depth of myometrial invasion, tumor grade and presence of lymphovascular invasion. Most recurrences are in the vaginal cuff. External beam radiation therapy targets any gross disease present, the
parametrial regions, upper vaginal and paravaginal tissues, as well as pelvic lymph nodes (lower common iliac, external iliac, internal iliac, presacral). IMRT techniques reduce the radiation dose to nearby critical pelvic structures, such as small bowel. External pelvic radiotherapy is the preferred treatment for stage IB grade 3 lesions and patients with involved nodes. A brachytherapy boost is appropriate for patients with endocervical or cervical stromal involvement. Whether external radiotherapy can be replaced by vaginal brachytherapy and chemotherapy for high risk stage I and stage II patients is currently being studied by the GOG. Vaginal brachytherapy alone is preferred for most other stage I patients based on the results of the PORTEC-2 randomized trial, although EBRT may be reasonable for those at especially high risk of LRR. As advocated in the 2014 Choosing Wisely campaign, stage IA patients with grade 1 or 2 disease and no other risk factors should be observed.

Uterine sarcomas are rare tumors arising in muscle or connective tissue. Postoperative radiation therapy is recommended for patients at high risk for pelvic recurrence after surgery. As with other gynecologic cancers, IMRT may be used to reduce the dose to the small bowel.

**Ovarian Cancer**

Radiation therapy is no longer a common component of initial treatment or consolidative therapy for primary epithelial ovarian cancer treatment. Standard of care includes surgical resection or debulking and systemic chemotherapy. Palliative radiation remains an option to manage symptoms in recurrent or metastatic disease.

For review of metastatic sites, please refer to specific guidelines for the appropriate location (e.g., CNS Cancers for brain metastases and Lung Cancer for lung metastases).

**Radiation Oncology Indications**

**2D or 3D Conformal is appropriate for gynecologic cancers when ANY of the following conditions are met**

- Primary disease, with or without chemotherapy, particularly to irradiate inguinal and/or pelvic lymph nodes **OR**
- Metastatic disease, particularly for palliation of symptoms

**Cervical Cancer**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for cervical cancer when the following condition is met

- To treat primary cervical cancer

Stereotactic Body Radiation Therapy (SBRT) is appropriate for cervical cancer when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for cervical cancer when the following condition is met

- To treat primary cervical cancer

**Fallopian Tube Cancer**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for fallopian tube cancer when the following condition is met

- To treat primary fallopian tube cancer

Stereotactic Body Radiation Therapy (SBRT) is appropriate for fallopian tube cancer when the following condition is met

- Only to treat a previously irradiated field
Ovarian Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for ovarian cancer when the following condition is met

- To treat primary ovarian cancer

Stereotactic Body Radiation Therapy (SBRT) is appropriate for ovarian cancer when the following condition is met

- Only to treat a previously irradiated field

Uterine Neoplasms (Endometrial Carcinoma, Uterine Sarcoma, Uterine Carcinosarcoma)

Intensity Modulated Radiation Therapy (IMRT) is appropriate for uterine neoplasms when the following condition is met

- To treat individuals with cancer of the uterus, including uterine sarcoma and endometrial carcinoma

Stereotactic Body Radiation Therapy (SBRT) is appropriate for uterine neoplasms when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for uterine neoplasms when the following condition is met

- To treat individuals with cancer of the uterus, including uterine sarcoma and endometrial carcinoma

Vulvar/Vaginal Cancer

Intensity Modulated Radiation Therapy (IMRT) is appropriate for vulvar/vaginal cancer when the following condition is met

- To treat vulvar/vaginal cancer

Stereotactic Body Radiation Therapy (SBRT) is appropriate for vulvar/vaginal cancer when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for vulvar/vaginal cancer when the following condition is met

- To treat individuals with vaginal or vulvar cancer

Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

3D Conformal

CPT

77295 3-dimensional radiotherapy plan, including dose-volume histograms

ICD-10 Diagnoses

Not specified
# Intensity Modulated Radiation Therapy

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77301</td>
<td>Intensity modulated radiation therapy plan, including dose-volume histogram for target and critical structure partial tolerance specifications</td>
</tr>
<tr>
<td>77338</td>
<td>Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan</td>
</tr>
<tr>
<td>77386</td>
<td>Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex partial tolerance specifications</td>
</tr>
<tr>
<td>G6015</td>
<td>Intensity modulated Treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session</td>
</tr>
<tr>
<td>G6016</td>
<td>Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session</td>
</tr>
</tbody>
</table>

## ICD-10 Diagnoses

- C51.0 - C51.9: Malignant neoplasm vulva
- C52: Malignant neoplasm vagina
- C53.0 - C53.9: Malignant neoplasm cervix
- C54.0 - C55: Malignant neoplasm uterus
- C56.1 - C56.9: Malignant neoplasm ovary
- C57.00 - C57.02: Malignant neoplasm fallopian tube
- C57.7 - C57.9: Malignant neoplasm other & unspecified female genital organs
- Z92.3: Personal history of irradiation

# Stereotactic Body Radiation Therapy

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77301</td>
<td>Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)</td>
</tr>
<tr>
<td>77338</td>
<td>Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77373</td>
<td>Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77435</td>
<td>Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77470</td>
<td>Special treatment procedure</td>
</tr>
<tr>
<td>G0339</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment</td>
</tr>
<tr>
<td>G0340</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment</td>
</tr>
</tbody>
</table>

## ICD-10 Diagnoses

- Z92.3: Personal history of irradiation

# Brachytherapy

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>55920</td>
<td>Placement of needles or catheters into pelvic organs and/or genitalia (except prostate) for subsequent interstitial radioelement application</td>
</tr>
<tr>
<td>57155</td>
<td>Insertion of uterine tandem and/or vaginal ovoids for clinical brachytherapy</td>
</tr>
<tr>
<td>57156</td>
<td>Insertion of a vaginal radiation afterloading apparatus for clinical brachytherapy</td>
</tr>
<tr>
<td>58346</td>
<td>Insertion of Heyman capsules for clinical brachytherapy</td>
</tr>
</tbody>
</table>
77295 3-dimensional radiotherapy plan, including dose-volume histograms
77316 Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)
77317 Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)
77318 Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)
77370 Special medical radiation physics consultation
77470 Special treatment procedure
77761 Intracavitary radiation source application; simple
77762 Intracavitary radiation source application; intermediate
77763 Intracavitary radiation source application; complex
77770 Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771 Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772 Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778 Intracavitary radiation source application, complex, includes supervision, handling, loading of radiation source, when performed

ICD-10 Diagnoses
C51.0 - C51.9 Malignant neoplasm vulva
C52 Malignant neoplasm vagina
C53.0 - C53.9 Malignant neoplasm cervix
C54.0 - C55 Malignant neoplasm uterus
D06.0-D06.9 Carcinoma in situ of cervix uteri
D07.0 Carcinoma in situ of endometrium
D07.1 Carcinoma in situ of vulva
D07.2 Carcinoma in situ of vagina
D07.39 Carcinoma in situ of other female genital organs [uterus]

References


Head and Neck Cancers (including Thyroid)

General Information

Commonly Used Modalities

Internal Radiation Therapy (Brachytherapy)

External Beam Radiation Therapy
- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Head and Neck Cancers are defined as cancers of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, glottic larynx, supraglottic larynx, ethmoid and maxillary sinus, nasal cavity, salivary glands (including Parotid), Mucosal Melanoma, and Head and Neck occult primary.

IMRT has demonstrated improvement for Head and Neck cancer irradiation by reducing long-term side effects in the oropharyngeal, paranasal sinus, and nasopharyngeal cancers by reducing the dose to salivary glands, temporal lobes, auditory and optic structures. The use of IMRT to other regions has similar benefits and may be administered at the discretion of the ordering physician. However, the use of IMRT for early stage (stages I, II) glottic cancer has not been well established. Definitive or consolidative radiation for head and neck lymphomas often includes similar anatomic targets the other head and neck malignancies and IMRT may be considered medically necessary to spare salivary function and prevent permanent xerostomia.

Differentiated thyroid cancers are most often treated with surgical resection, with or without radioactive iodine (RAI). External beam radiation is used in a variety of clinical situations, including inadequate RAI uptake, unresectable or incompletely resected disease, locoregional recurrence, and metastatic disease.

Anaplastic thyroid cancer represents a highly lethal malignancy, with no clearly effective treatment protocols. External beam radiation, with or without chemotherapy, may improve short-term survival, and can be used to palliate symptoms, particularly airway obstruction. IMRT techniques have been shown to reduce toxicity.

For review of metastatic sites, please refer to specific guidelines for the appropriate location (e.g., CNS for brain metastases, Lung for lung metastases).

Radiation Oncology Indications

2D or 3D Conformal is appropriate for head and neck cancer when ANY of the following conditions are met
- Primary disease, with or without chemotherapy OR
- Metastatic disease, particularly for palliation of symptoms

Head and Neck

Intensity Modulated Radiation Therapy (IMRT) is appropriate for head and neck cancers when ANY of the following conditions are met
- Glottic cancer, stage III and IV OR
- Other advanced head and neck cancers OR
- Lymphomas of the head and neck region OR
To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for head and neck cancer when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for head and neck cancer when the following condition is met

- To treat cancers including cancers of the lip, oral cavity, tongue (particularly base of tongue), tonsils, sinuses, nasopharynx, pharynx, and other neck cancers

---

**Thyroid**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for head and neck cancer when **ANY of the following conditions are met**

- Anaplastic thyroid cancer **OR**
- To treat node-positive or node-recurrent thyroid cancer requiring external beam radiation treatment **OR**
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for head and neck cancer when the following condition is met

- Only to treat a previously irradiated field

---

**Coding**

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

### 3D Conformal

**CPT**

77295 ................. 3-dimensional radiotherapy plan, including dose-volume histograms

**ICD-10 Diagnoses**

Not specified

### Intensity Modulated Radiation Therapy

**CPT**

77301 ................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications

77386 ................. Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex

77338 ................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

### Stereotactic Body Radiation Therapy

**CPT/HCPCS**

77295 ................. 3-dimensional radiotherapy plan, including dose-volume histograms
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)

Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)

Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions

Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions

Special medical radiation physics consultation

Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment

Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

Personal history of irradiation

Brachytherapy

CPT

3-dimensional radiotherapy plan, including dose-volume histograms

Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)

Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)

Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)

Special medical radiation physics consultation

Special treatment procedure

Intracavitary radiation source application; simple

Intracavitary radiation source application; intermediate

Intracavitary radiation source application; complex

Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel

Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels

Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels

Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed

All modalities except Stereotactic Body Radiation Therapy

Malignant neoplasm of the lip

Malignant neoplasm of tongue

Malignant neoplasm of gum

Malignant neoplasm of floor of mouth

Malignant neoplasm of other & unspecified parts of mouth

Malignant neoplasm of major salivary glands

Malignant neoplasm of tonsil & oropharynx

Malignant neoplasm of nasopharynx
C13.0 - C14.8........Malignant neoplasm of hypopharynx, other & ill-defined sites in the lip, oral cavity & pharynx
C30.0 - C31.9........Malignant neoplasm of nasal cavity, middle ear & accessory sinuses
C32.0 - C32.9........Malignant neoplasm of larynx
C73..........................Malignant neoplasm of thyroid gland
C76.0......................Malignant neoplasm of other & ill-defined sites of head, face & neck
Z92.3......................Personal history of irradiation

References


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Lung Cancer: Small Cell and Non-Small Cell

**General Information**

**Commonly Used Modalities**

Internal Radiation Therapy (Brachytherapy)

External Beam Radiation Therapy

- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)

**Radiation Oncology Considerations**

Radiation therapy has a potential role for the treatment of lung cancers in all stages of disease.

For non-small cell lung cancer, radiation may be used as an adjunct to surgery. It may also serve as definitive therapy in unresectable disease. For unresectable stage II and III disease, concurrent chemoradiotherapy is considered standard of care, when tolerated. 3D conformal radiation typically provides optimal coverage of tumor volumes. IMRT may improve dose-volume constraints, but at the expense of increasing the volume of normal tissue exposed to low doses of radiation. If normal tissue tolerances would be exceeded with 3D conformal planning, IMRT is considered medically necessary.

The optimal dose and fractionation for both definitive and palliative treatment of non-small cell lung cancer has been the subject of numerous clinical investigations. Based on several earlier phase I/II trials of dose escalation, RTOG 0617 compared standard-dose (60 Gy) with high-dose (74 Gy) conformal radiotherapy given concurrently with carboplatin and paclitaxel chemotherapy with and without the addition of cetuximab. There was no benefit from the use of cetuximab in either arm. Overall survival was better in the standard-dose arms (28.7 vs 20.3 mos, p < 0.004). Standard-dose radiotherapy also resulted in better median progression free survival (11.8 vs 9.8 mos), lower risk of severe esophagitis (7% vs 21%, p < 0.0001) and fewer treatment-related deaths. ASTRO recently published an evidence-based clinical practice guideline which concluded that the ideal external beam dose fractionation for curative intent chemoradiotherapy for non-small cell lung cancer is 60 Gy given in 2 Gy once daily fractions over 6 weeks. Dose escalation beyond 60 Gy was not recommended outside the setting of clinical trial. This guideline has also been endorsed by ASCO. When used without concurrent chemotherapy, the guideline recommends a minimum dose of 60 Gy.

In metastatic NSCLC where palliative treatment is being considered, the goal is to strike a balance between symptom relief, local control and treatment toxicity. ASTRO published a comprehensive evidence-based guideline on palliative radiotherapy in lung cancer. The guideline concluded that higher-dose/fractionation regimens (30-Gy/10-fraction or higher) may benefit patients with good performance status. These higher dose regimens are associated with significant adverse effects such as esophagitis. Shorter course treatment is recommended for patients with poor performance status. Despite this recommendation, Koshy et al. found that almost half of stage IV lung cancer patients received inappropriately high doses of radiation (defined as more than 15 fractions). A recent update of the ASTRO guideline now supports concurrent chemoradiotherapy with a platinum doublet in stage III patients with ECOG performance status of 0-2 and a life expectancy of at least 3 months.

Stereotactic radiation may be used as definitive therapy in earlier stages of disease for patients who may not be candidates for invasive surgery. Furthermore, stereotactic radiation may be recommended for local palliation or prevention of symptoms such as hemoptysis, obstruction, or pain.

Radiation therapy is also used in all stages of small cell lung cancer, either as definitive treatment in combination with chemotherapy, or as palliative therapy. Concurrent chemotherapy is preferred to sequential chemotherapy with RT. Target volumes are best defined with pretreatment PET/CT obtained at the time of
radiotherapy planning. Consolidative thoracic radiation may be beneficial to select patients with extensive stage disease who have significant responses to standard chemotherapy.

The utility of 2D radiation is likely limited to palliative treatment of metastatic disease.

The minimum standard used to treat intrapulmonary lesions is 3D conformal, with CT planning. PET/CT is noted to significantly improve targeting accuracy. Tumor motion should be accounted for.

The clinically appropriate use of more advanced modalities, such as IMRT and SBRT, are limited to specific clinical scenarios. It is the responsibility of the Radiation practice to create optimal treatment plans when evaluating modality choices for treatment.

For review of metastatic sites, please refer to specific guidelines for the appropriate location (e.g., CNS Cancers for brain metastases and Lung Cancer for lung metastases).

### Radiation Oncology Indications

2D or 3D conformal is appropriate for lung cancer when ANY of the following conditions are met

- Primary lung cancers, for adjuvant, neoadjuvant, or definitive local treatment **OR**
- Palliation of metastatic lesions in the lung particularly symptomatic tumors requiring local control **OR**
- Prophylactic Cranial Irradiation (PCI), when indicated (see also CNS guideline)

### Primary Lung Cancers

**Non-Small Cell Lung Cancer**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for non-small cell lung cancer when ANY of the following conditions are met

- For adjuvant or definitive treatment in the curative setting
  - When a 3D plan has been performed and dose-volume constraints would lead to unacceptable risk for normal lung tissue toxicity such that **all must apply**
    - V20 exceeds 30% with 3D conformal plan (the percent of normal tissues receiving 20 Gy or more accounts for more than 30% of normal lung) **AND**
    - The comparison of the 3D conformal plan and the IMRT plan demonstrates that the IMRT plan will reduce the V20 by 10% as compared to the 3D conformal plan **AND**
    - V5 would be less than 65% (the percent of normal tissues receiving 5 Gy or more accounts for less than 65% of normal lung) with IMRT **AND**
    - Tumor motion has been accounted for during planning **OR**
  - When a 3D plan has been performed and dose-volume constraints would lead to unacceptable risk of cardiac toxicity: (Any constraint below is exceeded)
    - More than 50% of the heart receives 30 Gy (V30 > 50%)
    - More than 35% of the heart receives 45 Gy (V45 > 35%)
    - More than 25% of the heart receives 50 Gy (V50 > 25%) **OR**
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for non-small cell lung cancer when ANY of the following conditions are met

- For an alternative to surgical resection when **all must apply**
  - Treatment intent is cure **AND**
    - There is no evidence of nodal or distant metastases based on conventional staging techniques (Stage IA, IB, or IIA with negative lymph nodes) **AND**
o Single lesion measuring less than or equal to 5 cm AND
o Lesion is inoperable for ANY of the following reasons:
  ▪ Tumor location OR
  ▪ Individual is not a surgical candidate due to a medical contraindication OR
• To treat a previously irradiated field

Endobronchial Brachytherapy is appropriate for non-small cell lung cancer when ANY of the following conditions are met
• Treatment of unresectable primary bronchial tumors that cannot be addressed by standard external beam radiotherapy techniques OR
• Palliative treatment of obstructing endobronchial tumors

Small Cell Lung Cancer
Intensity Modulated Radiation Therapy (IMRT) is appropriate for small cell lung cancer when ANY of the following conditions are met
• For definitive treatment in the curative setting
  o When a 3D plan has been performed and dose-volume constraints would lead to unacceptable risk for normal lung tissue toxicity such that (all must apply)
    ▪ V20 exceeds 30% with 3D conformal plan (the percent of normal tissues receiving 20 Gy or more accounts for more than 30% of normal lung) AND
    ▪ The comparison of the 3D conformal plan and the IMRT plan demonstrates that the IMRT plan will reduce the V20 by 10% as compared to the 3D conformal plan AND
    ▪ V5 would be less than 65% (the percent of normal tissues receiving 5 Gy or more accounts for less than 65% of normal lung) with IMRT AND
    ▪ Tumor motion has been accounted for during planning OR
  o When a 3D plan has been performed and dose-volume constraints would lead to unacceptable risk of cardiac toxicity: (Any constraint below is exceeded)
    ▪ More than 50% of the heart receives 30 Gy (V30 > 50%)
    ▪ More than 35% of the heart receives 45 Gy (V45 > 35%)
    ▪ More than 25% of the heart receives 50 Gy (V50 > 25%) OR
• To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for small cell lung cancer when the following condition is met
• Only to treat a previously irradiated field

Endobronchial Brachytherapy is appropriate for small cell lung cancer when ANY of the following conditions are met
• Treatment of unresectable primary bronchial tumors that cannot be addressed by standard external beam radiotherapy techniques OR
• Palliative treatment of obstructing endobronchial tumors

Metastatic Lesions in the Lung
Intensity Modulated Radiation Therapy (IMRT) is appropriate for metastatic lesions in the lung when the following condition is met
• Only to treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for metastatic lesions in the lung when ANY of the following conditions are met
• To treat a metastatic lesion (all must be met)
  o Patient with a single metastatic lesion measuring less than 5 cm AND
    ▪ Oligometastatic disease may be considered on a case-by-case basis
  o Individual has a good performance status (either must apply)
    ▪ ECOG Scale 0, 1, or 2 OR
    ▪ Karnofsky Scale greater than or equal to 70% AND
  o Extrapulmonary disease is stable or volume of disease is low with remaining treatment options AND
  o Intent is either:
    ▪ Curative OR
    ▪ Palliative, with a current symptom or anticipation of a symptom (for example, lesion is close to a major vessel and without local treatment, is anticipated to lead to hemoptysis or hemorrhage) OR

• To treat a previously irradiated field

*Note: When SRS/SBRT is being requested to treat a patient with oligometastatic disease with potentially curative intent, please refer to separate criteria in the Oligometastatic Extracranial Disease section of the Guidelines.*

Endobronchial Brachytherapy is appropriate for metastatic lesions in the lung when the following condition is met

• For palliative treatment of obstructing endobronchial tumors

**Fractionation**

*For the treatment of stage I–III non-small cell lung cancer with concurrent chemoradiotherapy, up to 30 fractions of thoracic radiotherapy are medically necessary*

*For the palliative treatment of stage IV non-small cell lung cancer, up to 15 treatments of thoracic radiotherapy are medically necessary*

**Coding**

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

**3D Conformal**

<table>
<thead>
<tr>
<th>CPT/HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77402</td>
<td>Radiation treatment delivery, &gt; 1 MeV; simple.</td>
</tr>
<tr>
<td>77407</td>
<td>Radiation treatment delivery, &gt; 1 MeV; intermediate.</td>
</tr>
<tr>
<td>77412</td>
<td>Radiation treatment delivery, &gt; 1 MeV; complex</td>
</tr>
</tbody>
</table>
Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 MeV

Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 MeV

Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 MeV

Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 MeV or greater

Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5 MeV

Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10 MeV

Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19 MeV

Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20 MeV or greater

Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 MeV

Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV

Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV

Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater

Intensity Modulated Radiation Therapy

ICD-10 Diagnoses

C34.00 - C34.92 ... Malignant neoplasm of bronchus & lung
C78.00 - C78.02 ... Secondary malignant neoplasm of lung

CPT/HCPCS

77301 .................. Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications

77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

77386 .................. Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex

G6015 .................. Intensity modulated treatment delivery, single or multiple fields/arc, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session

G6016 .................. Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

ICD-10 Diagnoses

C34.00 - C34.92 ... Malignant neoplasm of bronchus & lung
C78.00 - C78.02 ... Secondary malignant neoplasm of lung

Stereotactic Body Radiation Therapy

CPT/HCPCS

32701 .................. Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT)

77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms

77301 .................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)

77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)

77370 .................. Special medical radiation physics consultation
Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions

Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions

Special treatment procedure

Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment

Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

ICD-10 Diagnoses

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C34.00</td>
<td>Malignant neoplasm of bronchus &amp; lung</td>
</tr>
<tr>
<td>C78.00</td>
<td>Secondary malignant neoplasm of lung</td>
</tr>
<tr>
<td>D02.20</td>
<td>Carcinoma in situ bronchus &amp; lung</td>
</tr>
<tr>
<td>Z51.5</td>
<td>Encounter for palliative care</td>
</tr>
<tr>
<td>Z53.09</td>
<td>Surgery contraindicated</td>
</tr>
<tr>
<td>Z92.3</td>
<td>Personal history of irradiation</td>
</tr>
</tbody>
</table>

Brachytherapy

CPT

31643 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with placement of catheter(s) for intracavitary radioelement application

77295 3-dimensional radiotherapy plan, including dose-volume histograms

77316 Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)

77317 Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)

77318 Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)

77370 Special medical radiation physics consultation

77470 Special treatment procedure

77761 Intracavitary radiation source application; simple

77762 Intracavitary radiation source application; intermediate

77763 Intracavitary radiation source application; complex

77770 Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel

77771 Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels

ICD-10 Diagnoses

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C34.00</td>
<td>Malignant neoplasm of bronchus &amp; lung</td>
</tr>
<tr>
<td>C78.00</td>
<td>Secondary malignant neoplasm of lung</td>
</tr>
<tr>
<td>Z51.5</td>
<td>Encounter for palliative care</td>
</tr>
</tbody>
</table>

References


These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Lymphoma: Hodgkin and Non-Hodgkin

General Information

Commonly Used Modalities

External Beam Radiation Therapy

- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)
- Stereotactic Radiosurgery (SRS)

Radiation Oncology Considerations

Hodgkin Lymphoma

Hodgkin lymphoma is a malignancy of the lymphatic system with distinct clinical and pathologic features which set it apart from Non-Hodgkin lymphoma. The disease commonly affects lymph nodes in the mediastinum but can affect nodes and other lymphatic organs throughout the body. Occasionally, the bone marrow and liver are also involved. Pathologically, Hodgkin lymphoma is characterized by the presence of characteristic lymphocytes called Reed-Sternberg cells.

There are four distinct subtypes of Hodgkin lymphoma. About 80% of cases are termed nodular sclerosis Hodgkin lymphoma. The other types include lymphocyte-predominant, mixed cellularity and lymphocyte-depleted Hodgkin lymphoma. Over the years, treatment has evolved from radiotherapy or chemotherapy alone to a risk adapted approach of chemotherapy and involved site radiotherapy. Treatment intensity is also guided by treatment response on PET scan performed after multiple cycles of chemotherapy.

For favorable stage I and II disease, 20-30 Gy of involved site radiotherapy is given after chemotherapy. For bulky disease at presentation, doses of 30-36 Gy are appropriate. Although these doses are generally below the dose tolerance of the surrounding normal tissues, there are situations where advanced planning techniques are likely to result in a meaningful decrease in late toxicity from radiotherapy. Koeck et al. published a planning comparison of 3D versus IMRT for patients with unfavorable mediastinal Hodgkin lymphoma and found reduced mean heart and spinal cord doses with IMRT. Doses to the lungs and breasts were higher with 3D conformal radiation. The most pronounced benefits were seen in patients with lymph nodes anterior to the heart. Since IMRT has been shown to increase low dose exposure to the breasts and lungs, the potential benefit of cardiac sparing needs to be weighed against increased risks of breast and lung cancer, especially in female patients.

The role of IMRT in the treatment of non-mediastinal Hodgkin lymphoma has not been studied and therefore IMRT in these cases is considered not medically necessary.

Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphoma is a cancer arising in lymphocytes and includes all subtypes except Hodgkin lymphoma (described below). The disease most commonly involved B-cells but can involve other types of lymphocytes. Historically, lymphomas have been grouped based on histology into low grade, intermediate grade and high grade. Advances in tumor phenotyping has allowed more sophisticated subtyping to guide treatment.

Specific treatment depends on the grade and extent of disease. Treatments may include chemotherapy, immunotherapy or other targeted therapy, radiation therapy and stem cell transplantation. Some asymptomatic follicular (low grade) lymphomas may not require active treatment. In other cases, involved site radiotherapy alone or in combination with systemic therapy is used. Doses range from 20-36 Gy. Stage I and II diffuse large B-cell lymphoma is typically treated with combined chemotherapy and radiotherapy. The dose to the involved site is guided by the response to 3-6 cycles of R-CHOP chemotherapy. Doses of 30-36 Gy are given to consolidate complete responses while doses of 40-50 Gy are used to treat partial responses. Radiotherapy is also applied to bulky sites of involvement after chemotherapy in stage III and IV lymphoma. Lymphoma
including mucosal associated (MALT) lymphomas, mantle cell lymphoma, Burkitt’s lymphoma and others may involve radiotherapy with doses up to 45 Gy as part of the treatment.

Because the doses of radiation needed for non-Hodgkin lymphoma are lower than doses used for most other types of cancer, the need for advanced planning techniques such as intensity modulated radiation therapy (IMRT) is limited. As with Hodgkin lymphoma, IMRT is appropriate for mediastinal disease due to the proximity of the target to sensitive normal structures. For other sites, there are limited data regarding IMRT and therefore it is considered not medically necessary.

Radiation Oncology Indications

2D or 3D conformal

2D or 3D conformal is appropriate for Hodgkin and non-Hodgkin lymphoma when ANY of the following conditions are met

- Primary therapy OR
- Consolidative treatment after chemotherapy

Intensity Modulated Radiation Therapy (IMRT)

Intensity Modulated Radiation Therapy (IMRT) is appropriate for Hodgkin and non-Hodgkin lymphoma when ANY of the following conditions are met

- Hodgkin lymphoma involving the mediastinum
- Non-Hodgkin lymphoma involving the mediastinum

Stereotactic Body Radiation Therapy (SBRT) or Stereotactic Radiosurgery (SRS)

Stereotactic Body Radiation Therapy (SBRT) or Stereotactic Radiosurgery (SRS) is appropriate for Hodgkin and non-Hodgkin lymphoma when the following condition is met

- To treat a previously irradiated field

Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

3D Conformal

CPT

77295 .......... 3-dimensional radiotherapy plan, including dose-volume histograms

ICD-10 Diagnoses

Not specified

Intensity Modulated Radiation Therapy

CPT/HCPCS

77301 ............... Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex

Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session

Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

<table>
<thead>
<tr>
<th>ICD-10 Diagnoses</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin lymphoma, intrathoracic lymph nodes</td>
<td>C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C81.12 Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C81.22 Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C81.32 Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C81.42 Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C81.72 Other Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C81.92 Hodgkin lymphoma, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>Follicular lymphoma, intrathoracic lymph nodes</td>
<td>C82.02 Follicular lymphoma grade I, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.12 Follicular lymphoma grade II, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.22 Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.32 Follicular lymphoma grade IIIa, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.42 Follicular lymphoma grade IIIb, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.52 Diffuse follicle center lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.62 Cutaneous follicle center lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.82 Other types of follicular lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C82.92 Follicular lymphoma, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>Non-follicular lymphoma, intrathoracic lymph nodes</td>
<td>C83.02 Small cell B-cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.12 Mantle cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.32 Diffuse large B-cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.52 Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.72 Burkitt lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.82 Other non-follicular lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.92 Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>Other lymphomas, intrathoracic lymph nodes</td>
<td>C84.02 Mycosis fungoides, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.12 Sézary disease, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.42 Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.62 Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.72 Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.92 Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.22 Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C84.92 Other mature T/NK-cell lymphomas, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C85.12 Unspecified B-cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C85.22 Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C85.82 Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C85.92 Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes</td>
</tr>
</tbody>
</table>
Stereotactic Body Radiation Therapy

CPT/HCPCS

77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms
77301 .................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)
77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)
77370 .................. Special medical radiation physics consultation
77373 .................. Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77435 .................. Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
77470 .................. Special treatment procedure
G0339 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
G0340 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

ICD-10 Diagnoses

Z92.3 .................. Personal history of irradiation

Stereotactic Radiosurgery

CPT/HCPCS

77295 .................. 3-dimensional radiotherapy plan, including dose-volume histograms
77301 .................. Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)
77338 .................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)
77370 .................. Special medical radiation physics consultation
77371 .................. Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based
77372 .................. Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based
77432 .................. Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)
G0339 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
G0340 .................. Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

ICD-10 Diagnoses

Z92.3 .................. Personal history of irradiation

References


Oligometastatic Extracranial Disease

General Information

Radiation Oncology Considerations

Metastasis can occur when one or more cancer cells develop the capacity to enter the bloodstream and establish secondary tumors in distant organs such as the brain, lungs, liver and bone. While widespread metastatic disease is generally considered incurable, there exists a subset of patients with limited metastatic involvement who can potentially be cured of their disease. This state has been termed “oligometastatic” and is most commonly defined as having 3 or fewer metastatic lesions. In the past, aggressive metastasis-directed therapy largely consisted of surgical resection of lung and liver lesions. Radiotherapy was generally reserved for palliation of symptoms. Advances in system therapy and the widespread availability of stereotactic body radiation therapy have renewed interest in ablative therapy for oligometastatic disease.

Much of the data on treatment of oligometastatic cancer consist of single institution retrospective reviews. Several series have shown long-term benefit from resection of limited liver metastases in patients with colorectal cancer. Five-year disease-free survival rates approach 30% in this setting. Similarly, radiofrequency ablation of limited hepatic metastases from colorectal cancer has been shown to improve survival. A phase II randomized EORTC trial studied the addition of radiofrequency ablation to standard systemic therapy in 119 patients without extrahepatic disease. Ruers et al. recently reported an 8-year overall survival rate of 36% for patients randomized to radiofrequency ablation of liver lesions compared to 9% for patients receiving systemic therapy alone.

Stereotactic body radiation therapy (SBRT), also termed stereotactic ablative radiation therapy (SABR), has also been studied in the treatment of oligometastatic cancer. Control rates with this ablative technology approach 90%. Several prospective phase II studies have examined the potential benefit of SABR in oligometastatic disease. Gomez et al. reported results of a multi-institutional phase II randomized study of local consolidative therapy (LCT) versus maintenance therapy or observation. Patients with non-small cell lung cancer and 1-3 metastatic lesions were eligible for randomization only if disease had not progressed on chemotherapy. The study was stopped early due to a significant improvement in progression-free survival with LCT (11.9 months) versus maintenance only (3.9 mos) yielding a hazard ratio of 0.35 (p < 0.005). Iyengar et al. studied whether consolidative radiotherapy to the primary and up to 5 metastatic lesions would improve disease-free survival in NSCLC compared to maintenance chemotherapy alone. Twenty-nine patients were randomized. Disease-free survival in SABR-treated patients was 9.7 months compared to 3.5 months in the maintenance group (p < 0.01).

In a single-arm phase II study of SABR in 147 patients with up to 5 metastatic lesions, Sutera et al. report a 5-year overall survival rate of 43%. In addition to lung cancer, they treated colorectal, head and neck, breast, and prostate cancers among others. Although they allowed up to 5 metastatic lesions, 96.5% of patients had 3 or fewer lesions. On multivariate analysis, patients with a Karnofsky Performance Status (KPS) of 80 or less was associated with worse survival.

The phase II STOMP trial randomized men with castration-sensitive, oligometastatic prostate cancer recurrence to either ablative metastasis-directed therapy (MDT) or surveillance. There were 62 patients studied using androgen deprivation therapy (ADT)-free survival as the primary endpoint. Up to 3 metastatic lesions were allowed in either nodal or non-nodal sites and MDT included either surgery or SABR. At a median follow-up of 3 years, MDT resulted in a median ADT-free survival of 21 months versus 13 months with surveillance (HR 0.6, p = 0.11). Quality of life was similar in both groups at baseline, 3 months, and one year.

Initial results of the randomized SABR-COMET (NCT01446744) trial were recently reported. This randomized trial compared overall survival in patients with a controlled primary cancer and up to 5 metastatic lesions treated with either SABR to all oligometastatic lesions or palliative standard of care (SOC). Eligible patients had EGOC PS 0-1 and an estimated life expectancy of at least 6 months. A total of 99 patients were treated using a 1:2 ratio of SOC versus SABR. The most commonly treated primary cancer types included breast, colorectal, lung, and prostate. Although up to 5 oligometastatic lesions were allowed, 93% had 1-3 metastases. Overall survival
for the SABR-treated patients averaged 41 months versus 28 months seen with palliative SOC ($p = 0.09$). Median progression-free survival rates were 12 months and 6 months, respectively ($p = 0.001$).

### Radiation Oncology Indications

**Stereotactic Body Radiation Therapy (SBRT)** is medically necessary for extracranial oligometastatic disease when ALL of the following conditions are met:

- One (1) to three (3) metastatic lesions involving the lungs, liver, or bone **AND**
- Primary tumor is breast, colorectal, melanoma, non-small cell lung, prostate, renal cell, or sarcoma **AND**
- Primary tumor is controlled **AND**
- No prior history of metastatic disease **AND**
- Good performance status
  - ECOG 0, 1, or 2 **OR**
  - Karnofsky Scale greater than or equal to 70%

### Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

#### Stereotactic Body Radiation Therapy

**CPT/HCPCS**

- 77295 3-dimensional radiotherapy plan, including dose-volume histograms
- 77301 Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)
- 77338 Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)
- 77370 Special medical radiation physics consultation
- 77373 Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
- 77435 Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
- 77470 Special treatment procedure
- G0339 Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
- G0340 Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

#### Stereotactic Radiosurgery

**CPT/HCPCS**

- 77295 3-dimensional radiotherapy plan, including dose-volume histograms
- 77301 Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)

Special medical radiation physics consultation

Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based

Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based

Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)

Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment

Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

### Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery

#### ICD-10 Diagnoses

- **C18.0** - C18.9 Malignant neoplasm of colon
- **C19** - C20 Malignant neoplasm of rectum and rectosigmoid junction
- **C34.90** - C34.92 Malignant neoplasm of unspecified part of bronchus or lung
- **C40.0** - C40.92 Malignant neoplasm of bones of limb
- **C43.0** - C43.9 Malignant melanoma
- **C49.0** - C49.9 Malignant neoplasm of connective and soft tissue
- **C50.011** - C50.929 Malignant neoplasm of breast
- **C64.1** - C64.9 Malignant neoplasm of kidney, except renal pelvis
- **C68.8** - C68.9 Malignant neoplasm of urinary organ(s)
- **C79.5** Secondary malignant neoplasm of large intestine and rectum
- **C79.81** Secondary malignant neoplasm of breast
- **C7A.022-C7A.029** Malignant carcinoid tumor of the colon
- **C96.4** Soft tissue sarcoma of dendritic cells (accessory cells)
- **Z85.118** Personal history of other malignant neoplasm of bronchus and lung
- **Z85.3** Personal history of malignant neoplasm of breast
- **Z85.528** Personal history of other malignant neoplasm of kidney
- **Z85.820** Personal history of malignant melanoma of skin

#### References


Other Tumor Types: Sarcoma, Thymoma and Thymic Carcinoma, Pediatric Tumors, and Other Malignancies

General Information

Commonly Used Modalities

Internal Radiation Therapy (Brachytherapy)

External Beam Radiation Therapy

- 2D or 3D conformal
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)
- Stereotactic Radiosurgery (SRS)

Proton Beam: please see separate Proton Beam Radiation Therapy guideline

Radiation Oncology Considerations

Sarcomas

Soft tissue sarcomas are rare malignancies arising in connective tissue. Multimodality treatment with surgery, radiation and chemotherapy is common, especially in high grade sarcomas. Multiple studies have shown that radiation improves local control. Soft tissue sarcomas are often treated with preoperative therapy to a dose of 50 Gy. Placement of clips at the time of surgery aids with boost planning if needed. Alternatively, postoperative radiation therapy can be given. External beam treatment typically consists of 50 Gy to a larger field encompassing the preoperative tumor volume plus a margin followed by a smaller boost field. Boost doses of 10-26 Gy are used, depending on the final surgical margins. Brachytherapy may also be used postoperatively, particularly in the setting of microscopic or gross residual disease after resection. Alternatively, intra-operative radiation may be considered as boost treatment at the time of surgery.

In terms of radiation planning, the use of MRI imaging and CT based planning are recommended. IMRT is sometimes utilized, but is particularly helpful in the setting of pelvic or retroperitoneal sarcoma, to minimize toxicity in this high-risk anatomic region. IMRT for sarcomas in other regions remains an area of active investigation. A recent RTOG study of image guidance suggested that toxicity is lower when field size is reduced in conjunction with daily IGRT. Many of these patients were treated with IMRT. Other retrospective comparisons of conventional radiation and IMRT have been published. A study by Folkert reported recurrence rates for 319 consecutive patients, about half of whom were treated with IMRT. There was an association between IMRT and improved local control. The authors note, however, that other confounding factors such as the use of MRI in treatment planning may explain the difference. The use of IMRT for soft tissue sarcomas is appropriate for pelvic, retroperitoneal and extremity soft tissue sarcoma.

Thymoma and Thymic Carcinoma

Thymomas are rare tumors arising in epithelial cells within the thymus. They can be benign or malignant. For lesions which are resectable, complete thymectomy and excision of tumor is recommended. Radiotherapy is added for stage III disease or in cases where the tumor is unresectable or incompletely resected. Doses of 45-50 Gy are used after resection with clear or close margins. A dose of 54 Gy is used for microscopically positive margins and doses of 60-70 Gy are given for gross disease. Chemotherapy is used in advanced or metastatic disease. CT-based treatment planning is recommended, as is respiratory motion management if available. Much like mediastinal Hodgkin lymphoma, IMRT is appropriate in order to spare heart and lung tissue.
Pediatric tumor types

IMRT is a method to spare normal tissue from radiation damage, and reduce the risk of toxicity, complications, and secondary malignancy in normal tissues that are still developing. IMRT has demonstrated excellent potential in sparing the organs at risk while achieving good local control. Therefore, IMRT is helpful in treating pediatric tumors that are sensitive to radiation therapy. Please see proton beam guidelines for further details regarding use of protons in pediatric tumors.

Other tumor types

Intensity modulated radiation therapy (IMRT) and stereotactic radiation techniques are used in the setting of overlapping with a previously irradiated field, due to the risk of toxicity or complications.

For review of metastatic sites, please refer to specific guidelines for the appropriate location (e.g., CNS Cancers for brain metastases and Lung Cancer for lung metastases).

Radiation Oncology Indications

2D or 3D conformal

2D or 3D conformal is appropriate when ANY of the following conditions are met

- Primary malignancy diagnoses OR
- Metastatic lesions

Sarcoma

Intensity Modulated Radiation Therapy (IMRT) is appropriate for sarcoma when ANY of the following conditions are met

- For initial treatment of a primary pelvic soft tissue sarcoma OR
- For initial treatment of a primary retroperitoneal sarcoma OR
- For treatment of an extremity sarcoma OR
- To treat a previously irradiated field

Stereotactic Radiosurgery (SRS) is appropriate for sarcoma when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy (LDR or HDR) is appropriate for sarcoma when ANY of the following conditions are met:  

- When margins are involved OR
- When margins are closer than 5 mm

Thymoma and Thymic Carcinoma

Intensity Modulated Radiation Therapy (IMRT) is appropriate for treatment of thymoma and thymic carcinoma when ANY of the following conditions are met

- For treatment of a mediastinal thymoma or thymic carcinoma OR
- To treat a previously irradiated field

Stereotactic Radiosurgery (SRS) is appropriate for thymoma and thymic carcinoma when the following condition is met

- Only to treat a previously irradiated field

Pediatric individuals (age less than 21)

Intensity Modulated Radiation Therapy (IMRT) is appropriate for pediatric patients when the following condition is met
To treat pediatric individuals, age less than 21, with a radiosensitive tumor, Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT) is appropriate for pediatric patients **when ANY of the following conditions are met**

- To treat an intracranial malignancy (see CNS guidelines) **OR**
- To treat a previously irradiated field

**Note: see Proton Beam Guideline for Proton Beam indications**

### Other Malignancies

Intensity Modulated Radiation Therapy (IMRT) is appropriate for other malignancies **when the following conditions are met**

- Where risk of critical structure (heart, lung) exposure would be excessive with 3D conformal treatment (both must be met)
  - 3D planning has been done with appropriate techniques to limit toxicity, but organ at risk limits have been exceeded (based on QUANTEC limits*) **AND**
  - IMRT demonstrates improvement to tissue exposure to within safe ranges **OR**
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for other malignancies **when the following condition is met**

- Only to treat a previously irradiated field

### Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved.AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

### 3D Conformal

**CPT**

77295 ................. 3-dimensional radiotherapy plan, including dose-volume histograms

**ICD-10 Diagnoses**

Not specified

### Intensity Modulated Radiation Therapy

**CPT/HCPCS**

77301 ................. Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications

77338 ................. Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

77386 ................. Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex

G6015 ................. Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session

G6016 ................. Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session
### ICD-10 Diagnoses

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C37</td>
<td>Malignant neoplasm of thymus</td>
</tr>
<tr>
<td>C48</td>
<td>Malignant neoplasm of retroperitoneum</td>
</tr>
<tr>
<td>C49.10 - C49.12</td>
<td>Malignant neoplasm of connective and soft tissue of the upper limb</td>
</tr>
<tr>
<td>C49.20 - C49.22</td>
<td>Malignant neoplasm of connective and soft tissue of the lower limb</td>
</tr>
<tr>
<td>C49.4, C49.5</td>
<td>Malignant neoplasm of connective and other soft tissue of abdomen, pelvis</td>
</tr>
<tr>
<td>D15.0</td>
<td>Benign neoplasm of thymus</td>
</tr>
</tbody>
</table>

### Stereotactic Body Radiation Therapy

#### CPT/HCPCS

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77301</td>
<td>Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)</td>
</tr>
<tr>
<td>77338</td>
<td>Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77373</td>
<td>Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77435</td>
<td>Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</td>
</tr>
<tr>
<td>77470</td>
<td>Special treatment procedure</td>
</tr>
<tr>
<td>G0339</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment</td>
</tr>
<tr>
<td>G0340</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment</td>
</tr>
</tbody>
</table>

### ICD-10 Diagnoses

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z92.3</td>
<td>Personal history of irradiation</td>
</tr>
</tbody>
</table>

### Stereotactic Radiosurgery

#### CPT/HCPCS

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77301</td>
<td>Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (when specified as treatment planning for SRS or SBRT)</td>
</tr>
<tr>
<td>77338</td>
<td>Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan (when specified as devices for SRS or SBRT)</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77371</td>
<td>Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based</td>
</tr>
<tr>
<td>77372</td>
<td>Radiation treatment delivery, stereotactic radiosurgery (SRS) complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based</td>
</tr>
<tr>
<td>77432</td>
<td>Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)</td>
</tr>
<tr>
<td>G0339</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment</td>
</tr>
<tr>
<td>G0340</td>
<td>Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment</td>
</tr>
</tbody>
</table>

### ICD-10 Diagnoses

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z92.3</td>
<td>Personal history of irradiation</td>
</tr>
</tbody>
</table>
## Brachytherapy

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20555</td>
<td>Placement of needles or catheters into muscle and/or soft tissue for subsequent interstitial radionuclide application (at the time of or subsequent to the procedure)</td>
</tr>
<tr>
<td>77295</td>
<td>3-dimensional radiotherapy plan, including dose-volume histograms</td>
</tr>
<tr>
<td>77316</td>
<td>Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)</td>
</tr>
<tr>
<td>77317</td>
<td>Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)</td>
</tr>
<tr>
<td>77318</td>
<td>Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77470</td>
<td>Special treatment procedure</td>
</tr>
<tr>
<td>77761</td>
<td>Intracavitary radiation source application; simple</td>
</tr>
<tr>
<td>77762</td>
<td>Intracavitary radiation source application; intermediate</td>
</tr>
<tr>
<td>77763</td>
<td>Intracavitary radiation source application; complex</td>
</tr>
<tr>
<td>77770</td>
<td>Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel</td>
</tr>
<tr>
<td>77771</td>
<td>Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels</td>
</tr>
<tr>
<td>77772</td>
<td>Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels</td>
</tr>
<tr>
<td>77778</td>
<td>Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed</td>
</tr>
</tbody>
</table>

### ICD-10 Diagnoses

C49.0 - C49.9 | Malignant neoplasm of connective & other soft tissue

### References


Prostate Cancer

General Information

Commonly Used Modalities

- Internal Radiation Therapy (Brachytherapy)
- External Beam Radiation Therapy
  - 2D and 3D conformal
  - Intensity Modulated Radiation Therapy (IMRT)
  - Stereotactic Body Radiation Therapy (SBRT)

Radiation Oncology Considerations

Prostate cancer is the most common cancer seen in men. Early detection has resulted in a decrease in prostate cancer mortality over the past two decades.

Active surveillance options should be discussed with individuals with low-risk prostate cancers. Furthermore, individuals with low- or intermediate-risk prostate cancer and an anticipated survival of less than 10 years based on comorbidity are recommended to be followed with observation, as the risk of over-treatment may outweigh the clinical benefit.

External beam radiotherapy and surgery are the primary treatment modalities in patients who do not opt for surveillance. Improvement in radiation therapy delivery, including 3D-conformal radiation and IMRT, have allowed for the safe dose escalation which has improved cure rates in patients with localized disease. Pelvic nodal irradiation should be limited to individuals with intermediate-risk or high-risk disease.

There is a trend toward hypofractionation (fewer treatments to deliver the same biologic dose) which allows patients to be treated with less disruption of their daily lives. There have been several randomized clinical trials comparing conventionally fractionated external radiotherapy with hypofractionated regimens. RTOG 0415 was designed to evaluate the non-inferiority of hypofractionated treatment (70.8 Gy in 28 fractions) compared to conventional fractionation (73.8 Gy in 42 fractions). There were 1092 participants. At a median follow-up of 5.9 years, the estimated 5-year disease-free survival rate was 85.3% in the conventional radiotherapy arm and 86.3% in the hypofractionated radiotherapy arm. The hypofractionated arm was associated with a significant increase in late grade 2 and 3 gastrointestinal and genitourinary adverse events. Based on the DFS rates, hypofractionated radiotherapy was found to be non-inferior. In the HYPRO trial, patients with intermediate to high-risk prostate cancer were randomized to receive 78 Gy in 38 fractions or 64.6 Gy in 19 fractions. At 5-years, the relapse free survival rates for conventional fractionation versus hypofractionation were 77.1% and 80.5% respectively. Since the goal of the trial was to prove superiority of hypofractionation, the authors concluded that hypofractionation had not been proven superior to standard fractionation. Hypofractionation does appear non-inferior in this study. In the PROFIT trial, investigators randomly assigned patients with intermediate-risk prostate cancer to receive 78 Gy in 39 fractions or 60 Gy in 20 fractions. With 6 years of follow-up, biochemical disease free survival was the same in both groups. There were no differences in ≥ grade 3 late GI or GU toxicities reported. Five-year results of the CHHip trial were recently published. This was an open-label, randomized study looking at both effectiveness and toxicities. A total of 3216 men were included. They compared 74 Gy in 37 fractions over a period of 7.4 weeks with hypofractionated radiotherapy at 60 Gy in 20 fractions over a period of 4 weeks or 57 Gy in 19 fractions over a period of 3.8 weeks. At the 5 year follow-up, biochemical or clinical failure-free rates were 88.3% in the conventional 74-Gy group, 90.6% in the hypofractionated 60-Gy group, and 85.9% in the hypofractionated 57-Gy group. While bladder and bowel symptoms peaked sooner in the hypofractionated groups (4-5 vs 7-8 weeks), at 18 weeks, rates were similar for all groups. Long-term adverse effects were similar among the treatment groups. The authors concluded that the hypofractionated approach using 60 Gy in 20 fractions was non-inferior to standard fractionation using 74 Gy in 37 fractions.
In 2018, ASTRO, ASCO, and AUA published an evidence-based guideline on hypofractionated radiation therapy for localized prostate cancer. They defined moderate hypofractionation as daily fractions ranging from 240 cGy to 340 cGy and ultrahypofractionation as daily fractions > 500 cGy. The latter is given in up to 5 fractions of SBRT. In comparing moderately fractionated IMRT with conventionally fractionated treatment, the panel has recommended that hypofractionated therapy should be offered to men with low- or intermediate-risk prostate cancer who opt for active treatment. These recommendations were both considered strong, were based on high-quality evidence, and had 100% consensus. Moderate hypofractionation should also be offered for high-risk prostate cancer where pelvic nodes will not be treated based on 94% consensus. They recommended that men be counselled of a small increased risk of temporary GI toxicity with hypofractionated regimens but noted that late GI and GU toxicities were similar in hypofractionated and conventional treatments. The suggested fractionation patterns are either 6,000 cGy in 20 fractions or 7,000 cGy in 28 fractions.

Postoperative radiotherapy (EBRT/IMRT) can be delivered in either the adjuvant or salvage setting. Indications for adjuvant prostate bed radiotherapy include T3 primary, extracapsular disease, seminal vesicle involvement, and Gleason 8 or 9 disease and positive margins. Salvage radiotherapy is indicated in patients at risk for local failure who have a rising prostate specific antigen (PSA) level. When adjuvant radiation therapy is indicated, it should be given within 1 year of radical prostatectomy, but after any post-operative issues have stabilized.

SBRT for prostate cancer is an emerging modality. This technology delivers a high biologic dose of radiation over a short period of time. The hypofraction associated with SBRT shortens the treatment time to five visits, compared to the 7 to 9 weeks typically required for IMRT. This shortened treatment time is (one week vs 8 to 9 weeks) is appreciated by individuals. The key outcomes include both tumor control and toxicity, primarily focusing on acute and chronic rectal and genitourinary complications. While there have been no controlled studies directly comparing SBRT and alternative techniques of conformal therapy (for example, IMRT) many prospective case series and retrospective cohort studies of subjects with localized low-risk and intermediate-risk prostate cancer and prolonged life expectancies have consistently reported that SBRT is associated with an acceptable toxicity profile and tumor control that is comparable to other radiation techniques. As with other treatments for prostate cancer, it is unlikely that randomized comparisons will be performed. Published studies to date include single institution reports, multi-institutional phase I/II studies looking at dose and systematic reviews. Hannan has recently published five year results of a prospective phase I/II trial of SBRT in 91 low-risk to intermediate-risk patients. About two-thirds of the patients had intermediate-risk disease. Doses of 45-50 Gy in five fractions were given. The five year freedom from biochemical failure was 98.6%. Grade 3 or greater late urinary and gastrointestinal toxicities were 5.5% and 7%, respectively. The highest rates of toxicity were seen in the 50 Gy cohort and the authors recommend against this dose. At the lower doses, toxicities are similar to that seen in dose-escalated IMRT. The most recent systematic review of SBRT for prostate cancer looked at 1,472 patients in 14 studies. The most common fractionation ranged from 35-36.25 Gy in five fractions. Most of these reports were for patients treated with Cyberknife. Biochemical progression-free survival ranged from 81%-100%. Acute and late grade 3 urinary and gastrointestinal toxicities ranged from 0-0.5% (acute) to 0.5%-1.3% (late). In May 2013, ASTRO updated its Model Policy for SBRT and states "It is ASTRO’s opinion that data supporting the use of SBRT for prostate cancer have matured to a point where SBRT could be considered an appropriate alternative for select patients with low to intermediate risk disease."

The 2018 ASTRO, ASCO, and AUA guideline on ultrahypofractionated radiotherapy for prostate cancer recommends offering SBRT to men with low-risk disease, considers SBRT an option in intermediate-risk disease, and does not recommend SBRT for high-risk disease outside of a clinical trial or registry.

Brachytherapy or prostate implant is another option to deliver highly conformal doses to the prostate. For a low dose rate (LDR) implant, permanent radioactive seeds are implanted evenly throughout the gland under ultrasound guidance. For a high dose rate (HDR) implant, catheters are placed into the gland which is later irradiated as the high activity seed stops in fixed dwell positions throughout the volume. Recently, the ASCO/Ontario Guideline on brachytherapy for prostate cancer was updated. For low-risk patients, LDR brachytherapy is a proven option to surgery or external beam radiotherapy. For intermediate and high-risk patients, either LDR or HDR brachytherapy should be considered as boost options in appropriate patients. Studies have shown improved survival when brachytherapy is used in this setting compared to external treatment alone. Both I-125 and palladium-103 are reasonable isotopes for LDR brachytherapy. No recommendation could be made for or against the use of Cs-131. The panel could not make a recommendation regarding HDR monotherapy.
The use of an implanted hydrogel spacer between the prostate and rectum has been studied as a way to minimize rectal symptoms during and after definitive radiotherapy for adenocarcinoma of the prostate. The study’s statistical methodology and conclusions have been criticized, concluding that clinical benefit, if any, is minimal. A recent Cochrane review of interventions to reduce acute and late adverse GI effects of pelvic radiotherapy concluded that “low-certainty evidence on balloon and hydrogel spacers suggests that these interventions for prostate cancer RT may make little or no difference to GI outcomes.” The use of an implanted hydrogel spacer is not medically necessary.

For a discussion of proton therapy, please refer to the separate Proton Beam Therapy Guidelines.

Disease Definitions

Low-risk of recurrence (ALL must be present to qualify as low risk)
- Stage T1-T2a AND
- Gleason score of 6 AND
- Prostate-specific antigen (PSA) below 10 ng/mL

Intermediate-risk of recurrence (ANY one characteristic)
- Stage T2b to T2c OR
- Gleason score of 7 OR
- PSA 10-20 ng/mL

High-risk of recurrence (ANY one characteristic)
- Stage T3a OR
- Gleason score 8-10 OR
- PSA greater than 20 ng/mL

Localized disease
- T stage of T1-3a (tumor has spread through the capsule on one or both sides but has not invaded the seminal vesicles or other structures) AND
- N0 (no lymph node involvement)

Locally advanced disease
- Any T status with N1 disease (either no spread to lymph nodes or there has been spread to the regional lymph nodes) OR
- T3b and above, no distant metastatic disease beyond local lymph nodes

Distant metastatic disease
- Beyond the local lymph nodes

Radiation Oncology Indications

2D or 3D conformal is appropriate for prostate cancer when ANY of the following conditions are met
- Primary treatment of prostate cancer OR
- Palliative treatment of advanced disease

Low risk of recurrence
Intensity Modulated Radiation Therapy (IMRT) is appropriate for prostate cancer when ANY of the following conditions are met
• When anticipated survival is greater than 10 years OR
• To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for prostate cancer **when ANY of the following conditions are met**
• When anticipated survival is greater than 10 years OR
• To treat a previously irradiated field

Brachytherapy is appropriate for prostate cancer when the following condition is met
• Permanent low dose rate brachytherapy is used as monotherapy

*Note: Active surveillance is a reasonable alternative to radiation treatment in individuals with low risk prostate cancer.*

**Intermediate risk of recurrence**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for prostate cancer **when ANY of the following conditions are met**
• When anticipated survival is greater than 10 years OR
• To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for prostate cancer when the following condition is met
• When anticipated survival is greater than 10 years OR
• To treat a previously irradiated field

Brachytherapy, consider as a boost in combination with external beam radiotherapy. **EITHER of the following is appropriate**
• Low-dose rate (LDR) brachytherapy OR
• High-dose rate (HDR) brachytherapy

**High risk of recurrence**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for prostate cancer **when ANY of the following conditions are met**
• Localized disease and locally advanced disease
  o With or without brachytherapy OR
• To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for prostate cancer when the following condition is met
• Only to treat a previously irradiated field

Brachytherapy is appropriate for prostate cancer when the following condition is met
• Used in combination with external beam radiation

**Post-prostatectomy**

Intensity Modulated Radiation Therapy (IMRT) is appropriate for prostate cancer **when ANY of the following conditions are met**
• Adjuvant therapy, with no evidence of metastatic disease
  o Detectable PSA OR
Any adverse pathologic feature

- pT3 disease OR
- Pathology demonstrates positive margin(s) OR
- Gleason score 8-10 OR
- Seminal vesicle involvement or invasion OR
- Extracapsular extension

- Salvage therapy
  - Undetectable PSA becomes detectable and increases on 2 or more lab measurements OR
- To treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for prostate cancer when the following condition is met

- Only to treat a previously irradiated field

### Hydrogel spacer

The use of an implanted hydrogel spacer between the prostate and rectum is not medically necessary.

### Local recurrence

Intensity Modulated Radiation Therapy (IMRT) is appropriate for prostate cancer when the following condition is met

- Only to treat a previously irradiated field

Stereotactic Body Radiation Therapy (SBRT) is appropriate for prostate cancer when the following condition is met

- Only to treat a previously irradiated field

Brachytherapy is appropriate for prostate cancer when the following condition is met

- Low-dose rate (LDR) OR High-dose rate (HDR) brachytherapy
  - To treat a local recurrence following external beam radiation or primary brachytherapy

### Fractionation

When the above criteria are met, the following fractionation applies:

The recommended EBRT/IMRT fractionation to treat localized prostate cancer when the pelvic lymph nodes will not be treated is either 60 Gy in 20 fractions or 70 Gy in 28 fractions. In men with significant baseline obstructive urinary symptoms, conventional fractionation of up to 45 fractions is considered medically necessary.

Up to 45 fractions of EBRT/IMRT are medically necessary for localized or locally recurrent prostate cancer when the pelvic lymph nodes will be treated.

Up to 40 fractions of EBRT/IMRT are medically necessary as adjuvant treatment to the prostate bed after prostatectomy.

### Coding

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

### 3D Conformal

#### CPT

- **77295** 3-dimensional radiotherapy plan, including dose-volume histograms

#### ICD-10 Diagnoses

- **C61** Malignant neoplasm Prostate

### Intensity Modulated Radiation Therapy

#### CPT/HCPCS

- **77301** Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (IMRT treatment plan)
- **77338** Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
- **77385** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking when performed; Simple (includes breast cancer, prostate cancer and compensator-based IMRT)
- **G6015** Intensity modulated treatment delivery, single or multiple fields/ arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
- **G6016** Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

#### ICD-10 Diagnoses

- **C61** Malignant neoplasm Prostate

### Stereotactic Body Radiation Therapy

#### CPT/HCPCS

- **77295** 3-dimensional radiotherapy plan, including dose-volume histograms
- **77301** Intensity modulated radiation therapy plan, including dose volume histogram for target and critical structure partial tolerance specifications (IMRT treatment plan)
- **77338** Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
- **77370** Special medical radiation physics consultation
- **77373** Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
- **77435** Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions
- **77470** Special treatment procedure
- **G0339** Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
- **G0340** Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment

#### ICD-10 Diagnoses

- **C61** Malignant neoplasm Prostate
- **Z92.3** Personal history of irradiation

### Brachytherapy

#### CPT

- **55875** Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy
77295 ............... 3-dimensional radiotherapy plan, including dose-volume histograms
77316 .................. Brachytherapy isodose plan; simple (1-4 sources or 1 channel), includes basic dosimetry calculations (Do not bill 77300)
77317 .................. Brachytherapy isodose plan; intermediate (5-10 sources or 2-12 channels), includes basic dosimetry calculation (Do not bill 77300)
77318 .................. Brachytherapy isodose plan; complex (over 10 sources or over 12 channels), includes basic dosimetry calculations (Do not bill 77300)
77370 .................. Special medical radiation physics consultation
77470 .................. Special treatment procedure
77771 .................. Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772 .................. Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778 .................. Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed

Rectal Spacer

CPT

55874 ............... Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed

ICD-10 Diagnoses

C61 .................. Malignant neoplasm Prostate
Z92.3 ............... Personal history of irradiation

References


The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
## Appendix 1 – CPT Groupers

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Specific CPT codes for services should be used when available. Nonspecific or not otherwise classified codes may be subject to additional documentation requirements and review.

### Brachytherapy

<table>
<thead>
<tr>
<th>Grouper Type</th>
<th>Grouper ID</th>
<th>Grouper Name</th>
<th>Included Codes</th>
<th>QTY Sent</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>77761</td>
<td>Delivery</td>
<td>77761, 77762, 77763, 76965, 77767, 77768, 77770, 77771, 77772, 77778</td>
<td>12</td>
</tr>
<tr>
<td>C</td>
<td>77790</td>
<td>Handling</td>
<td>77790</td>
<td>5</td>
</tr>
<tr>
<td>C</td>
<td>77316</td>
<td>Isodose Calc</td>
<td>77316, 77317, 77318, 77295</td>
<td>5</td>
</tr>
<tr>
<td>C</td>
<td>Q3001</td>
<td>Handling</td>
<td>Q3001</td>
<td>n</td>
</tr>
<tr>
<td>A</td>
<td>43499</td>
<td>esophagus (esophageal tumor)</td>
<td>43499</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>47999</td>
<td>biliary tract (cholangiocarcinoma)</td>
<td>47999</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>55899</td>
<td>penile tumor</td>
<td>55899</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>67218</td>
<td>retina</td>
<td>67218</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>19296</td>
<td>breast</td>
<td>19296, 19297, 19298</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>20555</td>
<td>muscle and/or soft tissue</td>
<td>20555</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>41019</td>
<td>Head and/or neck region (percutaneous, transoral, or transnasal)</td>
<td>41019</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>55860</td>
<td>prostate</td>
<td>55860, 55862, 55865, 55875, 76873, G0458</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>55920</td>
<td>pelvic organs and/or genitalia (except prostate)</td>
<td>55920</td>
<td>3</td>
</tr>
<tr>
<td>A</td>
<td>31643</td>
<td>Bronchoscopy</td>
<td>31643</td>
<td>2</td>
</tr>
<tr>
<td>A</td>
<td>57155</td>
<td>Uterine tandems and/or vaginal ovoids, Heyman capsules, vaginal radiation afterloading apparatus</td>
<td>57155, 57156, 58346</td>
<td>5</td>
</tr>
</tbody>
</table>

### Intraoperative Radiation Therapy (IORT)

<table>
<thead>
<tr>
<th>Grouper Type</th>
<th>Grouper ID</th>
<th>Grouper Name</th>
<th>Included Codes</th>
<th>QTY Sent</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>77424</td>
<td>N/A</td>
<td>77424, 77425</td>
<td>1</td>
</tr>
<tr>
<td>C</td>
<td>77469</td>
<td>N/A</td>
<td>77469, 19294</td>
<td>2</td>
</tr>
</tbody>
</table>

### Intensity Modulated Radiation Therapy (IMRT)

<table>
<thead>
<tr>
<th>Grouper Type</th>
<th>Grouper ID</th>
<th>Grouper Name</th>
<th>Included Codes</th>
<th>QTY Sent</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>77385</td>
<td>Delivery</td>
<td>77385, 77386</td>
<td>n</td>
</tr>
<tr>
<td>C</td>
<td>77301</td>
<td>Planning</td>
<td>77301</td>
<td>2</td>
</tr>
<tr>
<td>C</td>
<td>77338</td>
<td>MCL</td>
<td>77338</td>
<td>3</td>
</tr>
</tbody>
</table>

### Proton Beam Radiation Therapy (PBRT)

<table>
<thead>
<tr>
<th>Grouper Type</th>
<th>Grouper ID</th>
<th>Grouper Name</th>
<th>Included Codes</th>
<th>QTY Sent</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>77520</td>
<td>Delivery</td>
<td>77520, 77522, 77523, 77525</td>
<td>n</td>
</tr>
<tr>
<td>C</td>
<td>61796</td>
<td>N/A</td>
<td>61796, 61797, 61798, 61799</td>
<td>5</td>
</tr>
<tr>
<td>C</td>
<td>63620</td>
<td>N/A</td>
<td>63620, 63621</td>
<td>5</td>
</tr>
<tr>
<td>Grouper Type</td>
<td>Grouper ID</td>
<td>Grouper Name</td>
<td>Grouper Included on Order when submitted Dx/Anatomy</td>
<td>Included Codes</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>--------------</td>
<td>-----------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>C</td>
<td>61800</td>
<td></td>
<td></td>
<td>61800</td>
</tr>
<tr>
<td>C</td>
<td>77432</td>
<td></td>
<td></td>
<td>77432</td>
</tr>
<tr>
<td>C</td>
<td>77435</td>
<td></td>
<td></td>
<td>77435</td>
</tr>
<tr>
<td>C</td>
<td>58030</td>
<td></td>
<td></td>
<td>58030</td>
</tr>
<tr>
<td>C</td>
<td>77301</td>
<td>Planning</td>
<td></td>
<td>77301</td>
</tr>
<tr>
<td>C</td>
<td>77338</td>
<td>MCL</td>
<td></td>
<td>77338</td>
</tr>
<tr>
<td>C</td>
<td>77295</td>
<td>Planning</td>
<td></td>
<td>77295</td>
</tr>
</tbody>
</table>

**Stereotactic Radiation Surgery (SRS)**

| P            | 77371      | Delivery     |                                                     | 77371, 77372, G0339, G0340 | n        |
| C            | 61796      |              |                                                     | 61796, 61797, 61798, 61799 | 5        |
| C            | 61800      |              |                                                     | 61800          | 3        |
| C            | 77432      |              |                                                     | 77432, 77435   | 5        |
| C            | 77301      | Planning     |                                                     | 77301          | 2        |
| C            | 77338      | MCL          |                                                     | 77338          | 3        |
| C            | 77295      | Planning     |                                                     | 77295          | c        |

**Stereotactic Body Radiation Therapy (SBRT)**

| P            | 77373      | Delivery     |                                                     | 77373, G0339, G0340 | n        |
| C            | 63620      |              |                                                     | 63620, 63621, 61796, 61797, 61798, 61799 | 5        |
| C            | 77435      |              |                                                     | 77435, 32701     | 5        |
| C            | 77301      | Planning     |                                                     | 77301          | 2        |
| C            | 77338      | MCL          |                                                     | 77338          | 3        |
| C            | 77295      | Planning     |                                                     | 77295          | c        |

**3D Conformal (EBRT)**

| P            | 77402      | Fraction     |                                                     | G6003, G6004, G6005, G6006, G6007, G6008, G6009, G6010, G6011, G6012, G6013, G6014, 77402, 77407, 77412 | n        |
| C            | 77295      | Planning     |                                                     | 77295          | 2        |

**Image Guided Radiation Therapy (IGRT)**

| P            | 77387      | IGRT         |                                                     | 77387, G6001, G6002, G6017, 77014 | C        |

**Special Treatment**

| P            | 77470      | Special radiation treatment |                                                     | 77470          | 1        |

**Special Physics Consult**

| P            | 77370      | Special radiation physics consult |                                                     | 77370          | 1        |

**Notes**

- When criteria are met for the primary grouper (Grouper Type P), all of the included codes are passed on the extract with the associated quantity. Any of the included codes may be billed up to the specified total quantity limit.
- The codes listed in Grouper Type C are also included in the extract.
- Associated codes (Grouper Type A) are included only for specific anatomic sites as listed.
### History

<table>
<thead>
<tr>
<th>Status</th>
<th>Review Date</th>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revised</td>
<td>06/10/2019</td>
<td>02/09/2020</td>
<td>Independent Multispecialty Physician Panel (IMPP) review. Added new criteria and discussion for Oligometastatic extracranial disease. Revised criteria for Special treatment procedure, Bone metastases, Head and neck cancer, and Prostate cancer (added Hydrogel spacer as not medically necessary). Revised fractionation for Bone metastases and Prostate cancer. Added discussion for CNS cancers and Prostate cancer. Added Appendix with CPT groupers.</td>
</tr>
<tr>
<td>Revised</td>
<td>05/01/2018</td>
<td>01/27/2019</td>
<td>IMPP review. Revised criteria for Breast cancer, Rectal cancer, Pancreatic cancer, Head and neck cancer, Lung cancer, Sarcoma. Added discussion for Prostate cancer.</td>
</tr>
<tr>
<td>Revised</td>
<td>11/01/2016</td>
<td>02/20/2017</td>
<td>IMPP review. Added fractionation for lung cancer.</td>
</tr>
<tr>
<td>Revised</td>
<td>08/27/2015</td>
<td>01/01/2016</td>
<td>IMPP review. Revised criteria for Breast cancer. Added new criteria for IGRT, Special treatment procedure and special physics consult, and Bone metastases.</td>
</tr>
<tr>
<td>Created</td>
<td>05/14/2014</td>
<td>11/03/2014</td>
<td>IMPP review. Original effective date.</td>
</tr>
</tbody>
</table>